Injectable Drug Data

Injectable Drugs Data of Banglamung Hospital, Department of Pharmacy, Chonburi

/

/
Aethoxyskelerol
(polidocanol)
1%, 2 ml
3%, 2 ml
- !"#$!%&'()'( (sclerosing of

varicosevein) 2 mg/ kg/ day
Intravariceal, Paravariceal
Direct IV, IV Infusion
Acetylcysteine
(Fluimucil)
Inj : 300 mg/ 3 ml
Oral : 200 mg/
Sachet
- Antidote E paracetamol 300 mg/ kg

FJX>:8# 3 A@> 150, 50 F%D 100 mg/ kg
? 9%Y (J
- :$!(M:8# 5% solution :$)$ ( 140 mg/ kg
? 9(#IE)$ ( 70 mg/ kg 3\] 4 ;9. L$AJ
17 dose
IV Infusion
- Antivirus: 5 - 10 mg/ kg :8#$ $IX 1 ;9.
3\ ] 8 ;9. $ $ 5 - 7 I$
- :$!(MA=(? 9f&@$34_b=I 250 mg/ m2 :;#
5 mg/ kg F%D 500 mg /m2 :;# 10 mg/ kg
Acyclovir
250 mg, 500 mg,
1 gm ; powder
(Zovirax)
Amikacin (Amikin)
500 mg/ 2 ml
IV Infusion
- Antibiotic (amminoglycoside)
- )$ (E 5 - 7.5 mg/ kg 3\12 ;9.
- )$ (:;#E I9?X'I$G9X!=$ 15 mg/ kg 8&'
1.5 gm :$A$'#I$
IM, Intermittent IV

!
D5W
- Direct IV : 3 - 5 $ 34
- IV Infusion : 30 - 60 $ 34
7$8 1:
A@>34_ 1: $ $ 15 $ 34
150 mg/ kg in 200 ml D5W A>@ 34_ 2: $ $ 4 ;9.
7$8 2 :
A>@ 34_ 3: $ $ 16 ;9.
50 mg/ kg in 500 ml D5W
7$8 3 :
100 mg/ kg in 1,000 ml D5W
D5W, D5S/2
- %D% E 250 mg :$$@Y %_$
D5S/4, D5S, NSS, 10 ml
RINGER
- %D% E 500 mg :$$@Y %_$
10 ml
- %D% E 1 gm :$$@Y %_$
20 ml
D5W, D10W, NSS
, D5S, D5S/2,
RINGER

!L&'L >:$" %D% E34_:;#G(#

100 - 200 ml
:8#E ;# ] B E:$ 60 $ 34
!f&_'3Y :8#!=(AI 9!"4E8 E
?X' renal tubular $#'E34_"\(
30 - 60 $ 34
" #/ $
- 8# 9:;#:$8<=>?@>ABCDED 3 !(&'$F, :$A$G)#94HDI?=
8'J8&(, KAG?, KA8I:L, !"#$!%&'(F)M>, AI 9($"N>
- Discard any unused solution.
- USFDA Preg Cat B
- 8%>%D% EF%D!L&'L >!MJG(# 24 )9.
- AI:8#8%>G(#JE paracetamol overdose 8 - 15 ;9
- !=(I=>!I4E$, 8$ I"_$, 8%'(%9?4JHI(a4D 8N'&@' b&_$A$
- !=( anaphylactic reaction G(#$#'E
- USFDA Preg Cat B
- 8%>%D% EAI:;#B E:$ 12 ;9. (E G9X94 preservative)
- 8%>b"9E F%#IG9XAI!MJGI#:$?N#!EM$!f D' L??D'$G(#
- :8#$@Y !f4E>f' (2000 - 3000 ml/ day) Hl'>$ crystaluria
:$;XI> 2 ;9. F
- %()$ (E F%D!f=_9;XI>DED!I% :8#:$A$G)#34_94 Cr
clearance 50 ml/ min/ 1.73 m2 8&'$#'EIX
- USFDA Preg Cat B
- A>?I 24 ;9. 34_'\m8BN9=8#'> F%D 24 ;9. :$?N#!EM$
- DI> :;#:$A$G)#KAG?, KA?J, bN#"N>' E\34_G(#JE :$
;$ ("N>] F%D:;#?=(?X'$!Hn$DED!I% $ $, A$G)#) ($@Y
- ?IL"'J G(#E=$)'>8N
- USFDA Preg Cat D

Aminophyllin
250 mg/ 10ml

/

/
- Bronchial asthma, Bronchodilator
- Loading 5 mg/ kg
- bN#HpIE CHF = 0.3 mg/ kg/ hr
- Normal = 0.6 mg/ kg/ hr
- Smoker = 0.9 mg/ kg/ hr

D5W, D10W,
0.45%NaCl, NSS,
RINGER
Direct IV (G9X$=E9:;#!$&_'>L :8#!MI!=$GH

' L3Y :8#!"4E;4I=?G(#), IV Infusion
Amphotericin B
(Fungizone )
50 mg ; powder
- Antifungal !=_9?#$ 0.25 mg/ kg F%D

!f=_9!Hn$ 0.7 t 1.5 mg/ kg/ day "N>"\(G9X!=$
1.5 mg/ kg/ day [G9X!=$ 50 mg/ day]
D5W
!
- Direct IV : :8# loading dose
:$ 20 - 30 $ 34
(G9XAI:8#!MI!=$ 25 mg/ min,
8 !=(' )# >!A4E>
AI8E\(X'$ 5 t 10 $ 34
F%#I:8#?X':$'? !MI34_%(%>)
- IV Infusion : G9X:8#!=$
25 mg/ min
%D% Eb>E 50 mg :$ D5W
250 - 500 ml

20 t 30 $ 34
:8#$ $ 2 - 6 ;9.
NSS
Ringer Lactate
Ampicillin
250 mg, 1gm ;
powder
IV Infusion
- Antibacterial 1 - 2 gm 3\ 4 - 6 ;9.
G9X!=$ 12 gm/ I$
IM, Direct IV, IV Infusion
D5W, D5S/2, NSS, - IM : 250 mg, 1 gm :$$@Y %_$

RINGER
0.9 ml F%D 3.4 ml ? 9%Y (J
- Direct IV : %D% E 250 mg :$
$@Y %_$ 5 ml F%D 1 gm :$$@Y
%_$ 7.4 ml
- IV Infusion : :$" %D% E34_G(#
'EX >$#'E 50 ml
- IM : 3 - 5 $ 34
- Direct IV : :8#;# ]
'EX >$#'E 3 t 5 $ 34
y# )$ (E 500 mg F%D
8 AI 9F>9 IX $@$
:8#$ $ 10 t 15 $ 34
" #/ $
- 8%>!L&'L >F%#IAI:;#B E:$ 24 ;9. !9&_'!MJ:$?N#!EM$
- DI> DI J Cimetidine, Ciprofloxacin, Erythromycin,
Clarithromycin
! : vital sign F%D side effect L E !;X$
nervousness, anxiety, tachycardia, A%&_$G"#, ' !L4E$
- USFDA Preg Cat C

- Test dose : :8#E 3 > IV :$)$ ( 0.1 mg/ kg [)$ (E
"N>"\(G9X!=$ 1 mg] infuse $ $ 30 t 60 $ 34
- ?=(? 9 : fever, pulse rate , BP 3\ 30 $ 34
$ $ 4 ;9. y# 94' X'$:8#E A@>?X'GH
- G9XAI:8#E $ $!=$ 5 I$
- 8# 9b"9:$ NSS, Ringer lactate
- 8%>%D% EF%#IA>?I 24 ;9. 34_'\m8BN9=8#'> 8&'
1 "H( 8C:$?N#!EM$
- USFDA Preg Cat B
- 8%>%D% EF%#I AI:;#B E:$ 1 ;9. 8&' 48 ;9. (8 ?I3Y
%D% E!Hn$ NSS)
- A$G)#34_G?G9X(4 ?#'>%()$ (E %>
- USFDA Preg Cat B

/

/

!
Amiodarone
(Cordarone)
150 mg/ 3ml
- B ID Ventricular fibrillation F%D unstable

ventricular tachycardia
)$ ( :8#E :$ 24 ;9. F )'> :8#E HD9 m
1000 mg FJX>:8#E !Hn$ 3 DED (>$4@
:$ 24 ;9. F
1. Rapid loading phase : $Y E 150 mg 9 !L&'L >(#IE
D5W 100 ml :8#:$!I% 9 IX 10 $ 34 '? !MI
15 mg/ $ 34 '? !MI"N>"\(G9X!=$ 30 mg/ $ 34
2. Slow loading phase : $Y E 34_!L&'L >F%#I9 360 mg
:8#:$!I% 6 ;9. '? !MI 1 mg/ $ 34
3. Maintenance infusion : $Y E 34_!L&'L >F%#I9 540
mg :8#:$!I% 18 ;9. '? !MI 0.5 mg/ $ 34
8%>L 24 ;9. F%#I:8#E !Hn$ :
Maintenance infusion : K(E:8#" %D% E34_!L&'L >F%#I
:$AI 9!)#9)#$ 1 t 6 mg/ ml :8#:$!I% 24 ;9. K(E94
'? !MI 0.5 mg/ $ 34 '? !MI' L!f=_9G(#? 9
?'J"$'>?X'E
- :$m434_:;#AI 9!)#9)#$9 IX 2 mg/ ml ?#'>:8#bX $
3 > Central venous catheter
D5W
- Rapid, Slow, Maintenance :;#

150 mg, 360 mg, 540 mg
:$ D5W LY $I$ 100 ml,
200 ml, 300 ml ? 9%Y (J
:$ 24 ;9. F :
- Rapid loading phase :
$Y E 150 mg 9 !L&'L >(#IE D5W
100 ml
- Slow loading phase :
F%D Maintenance infusion 18 ml
(6 amp) )'> Amiodarone 9 !L&'
L >(#IE D5W 500 ml G(#AI 9
!)#9)#$ 1.8 mg/ ml (900 mg/ 500
ml)
8%>L 24 ;9.:
- Maintenance infusion : :;#)$ (
E 34_?#'> 9 !L&'L >(#IE D5W
:8#G(#AI 9!)#9)#$ 1 t 6 mg/ ml
- " %D% E34_!L&'L >:$ D5W 34_
AI 9!)#9)#$ 1 t 6 mg/ ml !9&_''ENX
:$)I(F#ILD94' E\$ $ 24 ;9. y#
'ENX:$ Polyvinyl Chloride LD94' E\
2 ;9.

- 1.5 mg/ $ 34
!I% 10 $ 34
- 1 mg/ $ 34
!I% > 6 Hr
- 0.5 mg/ $ 34
!I% > 186 Hr
" #/ $
- y# " %D% E!L&'L >JL\:$B ;$Df% "?= PVC AI:;#
B E:$ 2 ;9. F%D" %D% E!L&'L >JL\:$B ;$DF#IAI:;#
B E:$ 24 ;9.
- !MJE :$'\m8BN9=?_Y IX 25 '>a F%DHl'>$F">
- DI> :;#:$"?494ABC, :;#XI9JE 34_3Y :8#!=( Torsades
de pointes 8%4!%4_E> :;#E :$!(M' E\?_Y IX 2 H| F%D8# 9
:;#:$!(M3 F!=(
7$
- G9XAI:;#E IV Amiodarone !Hn$!I% $ $9 IX 3 "H( 8C
- G9XF$D$Y :8#}4(E !)# 8%'(!%&'((Y K(E?> (AID3Y
!}f D:$m4}\!}=$!3X $@$) !$&_'>L 94AI 9!"4_E>!4_EIJ
G8%!I4E$ F%DAI 9($)'>K%8=? !;X$ AI 9($K%8=??_Y 'EX >
\$F> DJJ G8%!I4E$K%8=?%#9!8%I y# !Hn$GHG(#AI 9:8#E
K(E IV Infusion 'EX >;# ] !9&_'?#'> !H%4_E$L E }4(!Hn$
JHD3 $
- 8 :;#E }4(!Hn$DED!I% $#'EIX 1 "H( 8C JHD3 $
)$ ( 800 t 1600 mg/ I$
- 8 :;#E }4(!Hn$DED!I% 1 t 3 "H( 8C JHD3 $ )$ (
600 t 800 mg/ I$
- 8 :;#E }4(!Hn$DED!I% 9 IX 3 "H( 8C JHD3 $
)$ ( 400 mg/ I$
@A : DI$DI E "J"$ 9~$>> AI 9($K%8=??_Y
8I:L!?#$!MI ;
- USFDA Preg Cat D

/

/

!

" #/ $
Atropine sulfate
Inj. 0.6 mg/ ml
- :;#:$ Sinus bradychadia, heart block, asystole, idioventricular, slow junction rhythms
(cholinergic blocking agents) B ID sinus bradycardia, antidote )'>" f=fI
organophosphate

:
- Preanesthetic : Oral, IM, IV, SC : $@Y 8$ < 5 kg: 0.02 mg/ kg/ dose
:8#X'$bX ?( 30 - 60 $ 34 ' L:8#?X'3\ 4 t 6 ;9. ? 9AI 9LY !Hn$
$@Y 8$ > 5 kg : 0.01 t 0.02 mg/ kg/ dose y~>)$ ("N>"\( 0.4 mg/ dose X'$bX ?(
30 t 60 $ 34 )$ (?_Y "\( 0.1 mg
- Bradycardia : IV, intratracheal : 0.02 mg/ kg )$ (?_Y "\( 0.1 mg )$ ("N>"\(?X'A@> 0.5 mg
:$!(M F%D 1 mg :$bN#:8<X ' L:8#@Y G(#3\ 5 $ 34 L$G(#)$ (E I9G9X!=$
1 mg :$!(M F%D 2 mg :$bN#:8<X
- Bronchospasm : Inhalation : 0.03 t 0.05 mg/ kg/ dose I$%D 3 t 4 A@>
:
- Asystole : IV ; 1 mg @Y G(# 3\ 3 t 5 $ 34? 9AI 9LY !Hn$
- Preaneathetic : IM, IV, SC ; 0.4 t 0.6 mg X'$bX ?( 30 t 60 $ 34 :8#@Y G(#3\ 4 t 6 ;9.
- Bradycardia: IV ; 0.5 t 1 mg 3\ 5 $ 34 Total. Max 2 mg 8&' 0.04 mg/ kg
- B ID Neuromuscular blockade : IV 25 t 30 mcg/ kg :8#X'$:8#E Neostigmine
30 I=$ 34
- Bronchospasm : inhalation : 0.025 t 0.05 mg/ kg/ dose 3\ 4 t 6 ;9.
()$ (E "N>"\( 5 g/ dose)
- f=L Organophosphate 8&' Carbamate : IV 1 t 2 mg/ dose 3\ 10 t 20 $ 34 L$IX LD
!=( atropine effect ?X'GH:8#E 3\ 1 t 4 ;9. !Hn$!I% 'EX >$#'E 24 ;9. )$ (E I9"N>"\( 50
mg :$ 24 ;9. F m4 severe intoxication ' L:8#)$ (E I93@>89("N>y~> 2 g
- 8# 9b"9J IV solution
- :$ Cadiac asystole $@$ total dose
G9XAI!=$ 2.5 mg :$ 2 ;9. A~_>
- E ' L94"XI$b"9)'> Sodium
metabisulfite ~_>' LX':8#!=(
Ff#G(#
- :;#E :$)$ (?_Y ] (0.1 mg) ' L
3Y :8#!=( paradoxical bradycardia
G(#
- G9XAI:8#y# heart rate >
60 beat/ min
overdose : dilated,
unreactive pupils, blurred vision,
dryness of mucous membrane,
urinary retention, tachycardia,
hyperthermia, hypertension
E$A : !MJ34_'\m8BN9=
?_Y IX 30 '>a !%!4E" 8# 9F;XF)M>
F%D!MJ:8#f#$F">
- ">!?' tachycardia y# bN#HpIE
94KA8I:LXI9(#IE
IM, IV, SC
- USFDA Preg Cat C

Atracurium
besylate
(Tracium)
25 mg/ 2.5 ml

/

/

- !Hn$ neuromuscular blocker of choice "Y 8JbN#HpIE NSS, D5W,

34_94B ID 3Y > $)'>?J8&'G?JfX'> :;#"Y 8J
D5S
A% E%# 9!$&@'!f&_' :"X endotracheal tube 8&':$
bX ?( G9X943=D>JHI(
Lactate

1
2 :
Ringer Sol.
!=_9?#$:8# 0.3 t 0.4 mg/ kg, maintenance dose 0.25
mg/ kg

> 2 :
!=_9?#$:8# 0.4 t 0.5 mg/ kg , maintenance dose
0.08 t 0.1 mg/ kg 8%> :8#E A@>F 20 t 45 $ 34
' L:8#@Y G(# 3\ 15 t 25 $ 34
D8IX >bX ?( ; !=_9?#$ 9 t 10 mcg/ kg/ min,
maintained rate 5 - 9 mcg/ kg/ min
ICU ; Continuous IV : infusion 11 - 13 mcg/ kg/ min
!

" #/ $
- Direct IV ' LG9XLY !Hn$?#'>

!L&'L >E
- Intermittent infusion F%D
continuous infusion !L&'L >E
(#IE D5W 8&' NSS, D5NSS
(8# 9!L&'L >:$ LRI) K(E:;#
20 mg (2 ml) !L&'L >:$
" %D% E 98 ml LDG(#AI 9
!)#9)#$ 200 mcg/ ml (0.2 mg/
ml) 8&':;# 50 mg (5 ml) !L&'L >
:$" %D% E 95 ml. LDG(#AI 9
!)#9)#$ 500 mcg/ ml ( 0.5 mg/
ml )
- Direct IV :;#!}f D!9&_'

!=_9?#$:8#E !Hn$ loading
dose !3X $@$ K(E:8#E bX $
3 >" E:8#" $@Y 3 >8%'(
!%&'((Y :;#!I% 30 t 60
I=$ 34
- Intermittent Infusion : :8#
E 34_!L&'L >bX $3 >" E:8#
" $@Y K(EH%X'E" $@Y 34_!)#
$G(#JE :8#G8%!)# GH
f#'9JE
- Continuous infusion : :;#
"Y 8J bX ?(34_:;#
!I% $ $ K(E:;#8%>L
:8#FJJ direct injection K(E
:8#:$'? !MI
5 t 10 mcg/ kg/ min
- Initial bolus ' LG9X?#'>!L&'L >

- :8#3 > IV !3X $@$ G9XAI:8#3 > IM !$&_'>L LD3Y :8#!=(
Tissue Irritation
- 8%>L !L&'L >F%#IA>?I 24 ;9. 34_'\m8BN9=?N#!EM$8&'
'\m8BN9=8#'>
- A$G)#' L94AI 9($?_Y ?IF(> !f D94 8%_>)'>
Histamine F%D' L!=( Bronchospasm G(#F?XfJG(#$#'E
7$ :
- AI!?4E9E F%D!A&_'>9&'!f&_'"Y 8J;XIE;4I=?GI#
:$m4}\!}=$
- y# :;#XI9J Isoflurane 8&' Enflurane AI%()$ (E
Atracurium %> 33 % , y# :;#XI9J Halothane AI%()$ (
E Atracurium %> 10 %
- :$ :8#E AI:;#J!A&_'> Infusion pump
- AIDI> :;#E :$bN#HpIE34_94B ID Electrolyte Imbalance
8&' Dehydration ~_>LD3Y :8#!=( ''3=)'>E !H%4_E$GH
! : Vital signs ?IL?=(? 9D(J)'> muscle
relaxation F%DB ID 3Y > $)'>?JF%DG? (m4:;#:$
ICU)
F overdose : Respiratory depression, cardiovascular
collapse
! IV $ % &
- USFDA Preg Cat C

Benztropine
(Cogentin)
2 mg/ 2 ml
Cloxacliin
500 mg, 1 gm ;
Powder
Cotrimoxazole
(Sulfamethoxazole
400 mg +
Trimethoprim
80 mg )/ 5 ml

/

/

- Central Anticholinergic drug

- :$m4 Drug t induced EPS

> 3 : 0.02 t 0.05 mg/ kg/ dose :8#I$%D 1
t 2 A@>
: 1 t 4 mg/ dose :8#I$%D 1 t 2 A@>
- :$m4 Acute dystonia
bN#:8<X : IM, IV ; 1 t 2 mg
IM, Direct IV
- Antibiotic (Penicillins)
- )$ ( :8#E 500 mg t 1000 mg
3\ 6 ;9.

- Antibiotic (Sulfa Groups)
> 2

- )$ ( :;#E 3_IGH 8 t 12 mg )'> TMP/ kg/ day
FJX>:8#3\ 6 ;9.
- UTI (Max 4 I$), Shigellosis (Max 5 I$) :8#E 8 t
10 mg )'> TMP/ kg/ day FJX>:8#3\ 6, 8 8&' 12 ;9.
- Pneumocystic :8#E 15 t 20 mg )'> TMP/ kg/ day
FJX>:8#3\ 6 8&' 8 ;9.
- Sepsis (adults) :8#E 20 mg )'> TMP/ kg/ day FJX>
:8#3\ 6 ;9.
IV Infusion
!
- :8#E G(#K(EG9X?#'>!L&'L >

1 mg/ min
D5W, D5S, NSS - IM : %D% EE 250 mg :$$@Y %_$ - Direct IV : 3 t 4

(0.9%NaCl)
1.5 ml
$ 34
- Direct IV : %D% EE 500 mg :$ - Infusion : 1 - 3 ;9.
$@Y %_$ 8 - 10 ml
- Infusion : %D% EE :$" %D% E
34_:;#G(#'EX >$#'E 100 ml
NSS, D5W,
- !L&'L > : 1 amp :$" %D% E34_:;#
G9X!=$ 1 ;9. A~_>
D10W, RINGER G(#'EX >$#'E 125 ml ' L:;#!f4E> 75 (K(E3_IGH 60 t 90
ml G(#:$ E34_?#'>LY (H=9 m$@Y
$ 34)
! IM
Rapid
Direct IV
" #/ $
- $=E9:8#3 > IM
- ?#'>AIJA\9G9X:8#!=( electrolyte imbalance F%D
fluid imbalance DI> sign of anticholinergic toxicity
!;X$ H F8#>, 3#'>bN, %# 9!$&@''X'$F>, tachycardia
- USFDA Preg Cat C

- 8%>%D% EF%#IA>?I 24 ;9. 34_'\m8BN9=8#'> F%D 4 I$:$
?N#!EM$
- AI:8#3 > IV Infusion ;# ] %(' HI(F%DHl'>$
!=( Phlebitis
- USFDA Preg Cat B
- 8%>!L&'L >F%#IF%#IAI:;#B E:$ 6 ;9. y# " %D% E
!Hn$ D5W 94AI 9A>?I 24 ;9
- AI 9!)#9)#$"N>"\(34_%D% EG(#A&' 2 amp ?X'" %D% E
100 ml AI:;#B E:$ 2 ;9
- AI?IL CBC, LFT, renal function test, urinalysis
- USFDA Preg Cat C,D at near term

/

/
Calcium gluconate - Hl'>$F%D B ID hypocalcemia, :;#"Y 8J

10% , 10 ml
tetany, cardiac disturbances L B ID
hyperkalemia, calcium channel blockers toxicity
- B IDFA%!4E9:$!%&'(?_Y IV; continuous infusion
8&'FJX>:8#I$%D 4 A@>
Neonates: 200 t 800 mg/kg/day
Infant Children :
200 t 500 mg/ kg/ day
Adults : 2 - 15 g/ 24 hr
- Hypocalcemia tetany
Neonates 100 t 200 mg/ kg/ dose ' L? 9(#IE
500 mg/ kg/ day FJX>:8#I$%D 4 A@>
Infants Children :
100 t 200 mg/ kg/ dose ( 0.5 - 0.7 mEq/ dose) :8#
$ $9 IX 5 t 10 $ 34 ' L:8#@Y G(#3\ 6 t 8 ;9.
8&':8# infusion 500 mg/ kg/ day
Adults : 1 t 3 g ( 4.5 t16 mEq )
- Calcium channel blockers toxicity, magnesium
intoxication, cardiac arrest 34_94B ID hyperkalemia

: 100 mg/ kg/ dose
: 500 t 800 mg/ kg/ dose
Max. : 3 g/ dose

!

" #/ $
!L&'L >(#IE NSS "Y 8J

pediatric F%D neonate
LY !Hn$?#'>!L&'L >:8#94AI 9
!)#9)#$"N>"\(G9X!=$ 50 mg/ ml
:
- Direct IV ' L:8#K(EG9X?#'>
!L&'L >K(E94'? !MI)'> :8#E
0.5 t 2 ml/ min (200 mg/ min)
- Intermittent infusion '? !MI)'>
:8#E G9XAI!=$ 200 mg/ min
- Continuous infusion K(E:8#
" %D% E34_!L&'L >F%#I 1000 ml :$
!I% 12 t 24 ;9. '? !MI)'> :8#
E G9XAI!=$ 200 mg/ min
Pediatric Neonate :
- Direct IV K(E'? !MI)'> :8#E
"N>"\(!3X J 50 t 100 mg/ min
- Infusion AI:8#'EX >;# ] F%D
?=(? 9bN#HpIE'EX >?X'!$&_'> K(E'? !MI
"N>"\()'> :8#E !3X J 120 t 240
mg/ kg :$!I% 9 IX 1 ;9. 8&' 0.6
t 1.2 mEq Calcium/ kg :$!I%
9 IX 1 ;9.
- G9XAI:8#E FJJ SC F%D IM !$&_'>L LD3Y :8#

!=( tissue necrosis
- y# :8#!MILD3Y :8#!=( Vasodilation, %(D(J
AI 9($K%8=?, cardiac arrhythmias, syncope,
cardiac arrest
- y# D(J)'>FA%!4E9:$!%&'(9 IX 12 mg/
dL :8# NSS, IV fluid F%D Furosemide !f&_')J
FA%!4E9''F%D?=(? 9I(D(J)'> Potassium
F%D Magnesium I93@>3Y ECG !f&_'?=(? 9
!=(B IDF3#'$
- y# !=(B ID hypocalcemia LD3Y :8#!=(
%# 9!$&@'D?\F%D!M> y# !=(B ID
hypercalcemia LD3Y :8#!=( bradycardia (
3Y > $)'>DJJHD" 3 arrhythmias F%D
3Y > $)'>G?JfX'>
- AI:;#!)M9)$ (!%MF%D:8#3 > large vein !f&_'%(
!=(DA E!A&'>
! : AI 9($K%8=? 8 bN#HpIEN#"~HI(
J=!Im34_}4(:8#8E\(E 8&'%(AI 9!MI)'> :8#E
%>
- " %D% E34_!L&'L >F%#I94AI 9A>?I 24 ;9.
34_'\m8BN9=8#'>
E$A : '\m8BN9= 15 t 30 C
- USFDA Preg Cat C

Cefazolin
(Cefaben)
1g
Cefeplme
(Maxipime)
1g

/

/
- Antibiotic (Cephalosporins 1st generation )

> 1
: 25 t 100 mg/ kg/ day FJX>:8#3\
6 t 8 ;9. )$ ("N>"\(G9X!=$ 6 g/ day
: 250 t 2000 mg :8#3\ 6 t 12 ;9. (H?=
:8# 8 ;9. ) )$ ("N>"\(G9X!=$ 12 g/ day
Deep IM, Direct IV, Infusion
- Antibiotic (Cephalosporins 4th generation)

:
- Febrile neutropenia : IV; 50 mg/ kg :8#3\ 8
;9. $ $ 7 t 10 I$
- Uncomplicated skin/ soft tissue infection,
pneumonia, complicated/ uncomplicated UTI :
IV; 50 mg/ kg :8#I$%D 2 A@>
:
- Most infection: IV; 1 t 2 g :8#3\ 12 ;9. $ $ 7
t 10 I$ (' L:8#)$ ("N>IX $4@:$bN#34_?=(!;&@'
pseudomonas)
- UTI : IM, IV; 500 t 1000 mg :8#3\ 12 ;9.
- Febrile neutropenia : IV; 2 g :8#3\ 8 ;9. $ $ 7
I$ 8&'L$IX ' LD(4)~@$
Direct IV, IM

!

NSS, D5W, D10W, - IM : %D% EE 1 g :$$@Y %_$ - Direct IV : 3 - 5 $ 34

D5S/2, D5S,
2.5 ml
- Infusion : 30 - 60 $ 34
RINGER
- Direct IV : %D% EE 1 g :$
$@Y %_$ 7.5 - 10.5 ml
- Infusion : %D% E :$
" %D% E34_:;#G(#'EX >$#'E
50 - 100 ml
NSS, D5W, D10W, - IM : %D% E(#IE" %D% E34_ IV Infusion :$ 30 $ 34
SWFI, RINGER
:;#G(# 2.4 ml
- IV : !L&'L >:8#94AI 9!)#9)#$
100 mg/ ml
" #/ $
- 8%>%D% EF%#IA>?I 24 ;9. 34_'\m8BN9=8#'> F%DA>?I 7 I$
:$?N#!EM$
- D9(DI> :;#:$A$G)#G?G9X(4 DI> !=( anaphylaxis
D8IX > first dose
- 8# 9b"9I9J aminoglycoside
- USFDA Preg Cat B
- 8%>!L&'L >F%#I!MJ:$?N#!EM$G(# 7 I$F%D
24 ;9. 34_'\m8BN9=8#'>
- DI> !=( anaphylaxis :$ :8#E A@>F
- USFDA Preg Cat B

Cefoxitin
(Cefoxin) 1 g
Cefotaxime
(Claforan) 1 g

/

/

!

NSS, D5W, - Direct IV : 1 g :$$@Y %_$
D10W,
8&'" %D% E34_:;#G(# 10 ml
RINGER
- Infusion : :$" %D% E34_:;#
G(#'EX >$#'E 50 - 100 ml
- Antibiotic (Cephalosporins 3rd generation)

> 3

: IM, IV;
- Mild t moderate infection : 80 t 100 mg/ kg/ day FJX>
:8#3\ 4 t 6 ;9.
- Severe infection : 100 t 160 mg/ kg/ day FJX>:8#3\ 4
t 6 ;9. )$ ("N>"\(G9X!=$ 1.2 g/ day
- Preioperative prophylaxis : 30 t 40 mg/ kg :8#X'$
bX ?($ $ 30 t 60 $ 34 ? 9(#IE 30 t 40 mg/ dose 3\ 6
;9. :8#G9X!=$ 24 ;9. 8%>bX ?(
: IM, IV; 1 t 2 g :8#3\ 6 t 8 ;9. )$ ("N>"\(G9X!=$
12 g/ day
Direct IV, Infusion IV, IM (!$K)
- Antibiotic (Cephalosporins 3rd generation )
D5W, NSS

< 12 456 < 50 kg:
- ?=(!;&@'3_IGH 50 t 180 mg/ kg/ day FJX>:8#3\ 4 t 6 ;9.
- Meningitis : 200 mg/ kg/ day FJX>:8#3\ 6 ;9.
- Uncomplicated infection : IM, IV; 1 g 3\ 12 ;9.
- Moderate & severe infection: IM, IV; 1 t 2 g 3\ 8 ;9
- Septicemia : IV; 2 g 3\ 6 t 8 ;9.
: IM, IV; 1 t 2 g 3\ 6 - 8 ;9. )$ ("N>"\(G9X!=$ 12
g/ day
Direct IV, Intermittent IV Infusion
%D% Eb>E 1 g (#IE$@Y %_$

'EX >$#'E 10 ml F%#I
!L&'L >?X' (#IE" %D% E
34_:;#G(#

- Direct IV : 3 - 5 $ 34
- Infusion : 15 - 30 $ 34
- Direct IV : 3 - 5 $ 34
- Infusion : 30 - 60 $ 34
" #/ $
- 8%>%D% EF%#IA>?I 24 ;9. 34_'\m8BN9=8#'> F%D 7 I$
:$?N#!EM$
- DI> !=( anaphylaxis :$ :8#E A@>F F%D
:;#XI9JE 34_94f=?X'G?F%D:$bN#HpIEKAG?
- USFDA Preg Cat B

- 8%>%D% EF%#IA>?I 12 ;9. 34_'\m8BN9=8#'>F%D
5 I$:$?N#!EM$
- 8 :8# IM AIb"9 1 % lignocaine solution !f&_'J!3
' HI()mD}4(
- USFDA Preg Cat B

Ceftazidime
(Fortum)
1g
Ceftriaxone
(Rocephin)
1g

/

/

< 12 : IV; 30 t 50 mg/ kg/
dose :8#3\ 8 ;9. )$ ("N>"\(G9X!=$ 6 g/ day
: IM, IV; 500 t 2000 mg 3\ 12 ;9.
- )$ ( :8#E 1 - 2 g 3\ 24 ;9.
- Meningitis :8#E 2 g 3\ 12 ;9.
IM, Infusion
- Antibiotic (Quinolones)
Ciprofloxacin
(Ciprobay, cifloxin)
IV Infusion
400mg, 200 mg
Chloramphenicol
- Antibiotic (anaerobic)
- )$ ( :8#E 50 - 100 mg/ kg/ day
FJX>:8#3\ 6 ;9. )$ ("N>"\(G9X!=$ 4 g/ day
Chlorpheniramine
Inj. 10 mg/ml

- antihistamine 10 - 20 mg
bN#:8<X : 5 - 40 mg (IV injection AI:;#!I% }4($ $
IX 1 $ 34) )$ ("N>"\(G9X!=$ 40 mg/ day
!(M : 0.0875 mg/ kg 3\ 6 ;9.
SC, IM, IV (slowly !I% 1 $ 34)

!
NSS, D5W, D10W

,D5S/2 ,D5S/4
,D5S
- IM : 1 g :$$@Y %_$ 3 ml
- Direct IV : 1 g :$$@Y %_$
10 ml
- Infusion : :$" %D% E34_
:;#G(#'EX >$#'E 50 - 100 ml
D5W, D10W, NSS, - IM : 1 g :$$@Y %_$8&'
D5/NSS, D10/NSS " %D% E34_:;#G(#'EX >$#'E
9.6 ml
:;#G(#'EX >$#'E 50 - 100 ml
NSS, RINGER ,
!L&'L >:8#94AI 9!)#9)#$
D5W, D10W
1 - 2 mg/ml
D5W, D10W,
D5S/2, D5S/4,
RINGER
- Direct IV : 1 g :$$@Y %_$

10 ml
:;#G(#'EX >$#'E 50 - 100 ml
G9X?#'>!L&'L >

- Direct IV : 3 - 5 $ 34
- Infusion : 30 - 60 $ 34
- Infusion: 30 - 60 $ 34
- IV bolus: %D% EE 1 g
:$ SWFI 10 ml }4($ $
2 t 4 $ 34
IV Infusion ;# ] B E:$
60 $ 34
- Direct IV : 1 $ 34
- Infusion : 30 - 60 $ 34
! IM
+ ,
-% . ! ID
/ 0 100mg/ mL
!
Intravenous
" #/ $
- 8%>%D% EF%#IA>?I 24 ;9.34_'\m8BN9=8#'> F%D 4 I$:$?N#
!EM$
- ">!? phelebitis F%D!H%4_E$ IV site 3\ 48 - 72 ;9.
- USFDA Preg Cat B
- 8%>!L&'L >F%#IA>?I 24 ;9. 34_'\m8BN9=8#'>F%D
10 I$:$?N#!EM$
- ">!? phelebitis F%D!H%4_E$ IV site 3\ 48 - 72 ;9.
- USFDA Preg Cat B
- 8%>!L&'L >E !MJ:$?N#!EM$F%D34_'\m8BN9=8#'> (25 '>a )
G(#$ $ 2 "H( 8C
- USFDA Preg Cat C
- 8%>!L&'L >F%#IA>?I 30 I$ 34_'\m8BN9=8#'> F%D 6 "H( 8C
:$?N#!EM$
- AIHJ)$ (:$bN#HpIEKA?JG?
- AI?IL CBC, LFT, Kidney function test
- USFDA Preg Cat C
- USFDA Preg Cat B

Cyclophosphamide
1g
Cyclosporine
(Sandimmune
Inj. 50 mg/ ml (5ml)
Dexamethasone
4 mg/ ml

/

/
- Antineoplastic Agent, Alkylating Agent

:
- SLE : IV; 500 t 750 mg/ m2 3\!(&'$ )$ (
"N>"\(G9X!=$ 1 g/ m2
- JRA/ Vasculitis : IV; 10 mg/ kg 3\ 2 "H( 8C

: IV; 400 t 1800 mg/ m2 (30 t
50 mg/ kg) ?X' :$ 1 A'C" (1 - 5 I$)
" 9 y:8#@Y G(#:$DED!I% 2 - 4 "H( 8C
IV Infusion, Intermittent IV

!
NSS
%D% Eb>E 1 g :$" %D% E

34_:;#G(# 50 ml
- Immunosuppressant agent
D5W, NSS
- )$ ( :8#E 5 - 6 mg/ kg
(0.9%NaCL)
Single dose 4 - 12 ;9. :8#8$~_>I$X'$ !H%4_E$
'IEID
IV Infusion
- Coticosteroid, Antinflammatory
NSS, D5W

Diclofenac
(Voltaren)
75 mg/ 3 ml
Dimenhydrinat
(Divomit)
50 mg/ 2 ml
- Analgesic, NSAIDs
- )$ ( :8#E 50 - 150 mg / day
IM
- Antiemetics
- )$ ( :8#E 50 - 100 mg 3\ 4 ;9
IM, Direct IV
D5W, NSS,
RINGER
- IV Infusion b"9E 1 ml
(50mg) :$ 20 - 100 ml )'>
D5W 8&' NSS
8%>b"9G9X?#'>$F">

IV Infusion : 20 - 30
$ 34
-% ! IV
single dose 4 - 12 ;9
X'$
transplantation 8$~_>I$
L$D3_>:8#E
JHD3 $G(#
< 20 mg : > 1 - 3 $ 34
> 20 mg : 7.5 $ 34
Infusion : :8#? 9Ff3EC
"_>
G9X?#'>!L&'L >
- IM, Direct IV : G9X?#'>!L&'L >

- Infusion : !L&'L >:$
" %D% E34_:;#G(# 50 t 100 ml
- Direct IV : %D% EE 50 mg
:$" %D% E34_:;#G(# 10 ml
B E:$ 2 $ 34
" #/ $
- 8%>b"9E F%#I:8#:;#B E:$ 24 ;9.
- 8 !MJE :$?N#!EM$LD94' E\ 6 I$8%>L I$34_b"9
- AIHJ)$ (E :$bN#HpIEKA?JF%DG?
- :;#E 'EX >D9(DI>:$bN#HpIE bone marrow suppresion
- USFDA Preg Cat D

- 8# 9F;X!EM$ !MJ:8#f#$F">
- E }4(8%>b"934_'\m8BN9= 25 '>a !MJ:$y\>f% "?= PVC
G(#$ $ 6 ;9. !MJ:$B ;$DF#IG(#$ $ 24 ;9.
- IV dose = 1/ 3 PO dose
- USFDA Preg Cat C
- 8%>L !L&'L >F%#I:;#B E:$ 24 ;9. F%D!MJ:$?N#!EM$G(# 2
I$
- $=E9:8#3 > IM :$NHFJJ)'> Acetate injection
- USFDA Preg Cat C, Din 1st trimester
- F$D$Y :8#3 >%# 9!$&@'"DKf%~]
- USFDA Preg Cat B:D in 3rd Trimester or near delivery
- A>?I 10 I$34_'\m8BN9=8#'>
- USFDA Preg Cat B

Dihydralazine
injection

/

/
- B IDAI 9($K%8=?"N>34_\$F>

!

" #/7$
NSS, SWFI
- Direct IV $Y b>E %D% E(#IE$@Y %_$34_

G(#9 JE LY $I$ 2 ml
-IV Infusion ?#'>$Y 9 !L&'L >?X'K(E$Y
25 mg 9 !L&'L >(#IE NSS !3X $@$ 8# 9
b"9J%NKA"!$&_'>L ?IE LD"% E?I
'EX >I(!MI
- Direct IV :8# 6.25 mg

}4(;# ] 'EX >$#'E 2 $ 34
y# LY !Hn$?#'>:8#@Y AI!I#$
DED$ $ 20 t 30 $ 34
X'$ AII(AI 9($K%8=?
F%D'? !?#$)'>8I:L
?%'(!I%
- IV Infusion )$ (E 34_:;#
A&' 25 mg
- 8%>L %D% EE F%#IAI:;#3$34 8# 9F;X!EM$!$&_'>L E

LD??D'$
7$
- }4(E AI:8#(#IEAI 9D9(DI>F%D:8#'ENX:$AI 9(NF%
)'>Ff3EC'EX >:%#;=( (y# !Hn$GHG(#:8#bN#HpIE$'$
K>fE J %)
- DI> !=( postural hypotension 8%> :8#E
! : AIIAI 9($K%8=?F%D'? !?#$)'>8I:L
?%'(!I%
overdose : AI 9($K%8=??_Y 8I:L!?#$b=(L>8ID
shock
!MJ : '\m8BN9=D8IX > 15 t 30 C
- USFDA Preg Cat C

Diazepam
(Valium)
10 mg/ 2ml

/

/
- Benzodiazepine, :;#:$B ID anxiety
disorders, panic disorders :;#!Hn$E ">J

D>JHD" 3 E D>J; :;#:$ alcohol
withdrawal symptoms

: - "Y 8J">JD>J8&'A% E%# 9!$&@'
8&'A% E>I% : IM, IV : 0.04 t 0.3 mg/ kg/
dose 3\ 2 t 4 ;9. L$G(#)$ (E "N>"\(
0.6 mg/ kg B E:$ 8 ;9.
- Status Epilepticus : 3 ' E\ 30 I$ t 5 H|
IV : 0.05 t 0.3 mg/ kg/ dose :8#E $ $IX 3
$ 34 :8#@Y G(#'43\ 15 t 30 $ 34 )$ ("N>"\(
G9X!=$ 5 mg
!(M9 IX 5 H| IV : 0.05 t 0.3 mg/ kg/
dose :8#E $ $IX 3 $ 34 :8#@Y G(#'43\ 15
t 30 $ 34 )$ ("N>"\(G9X!=$ 10 mg
: - "Y 8J">JD>J8&'A% E%# 9!$&@'
8&'A% E>I% : IM, IV : 2 t 10 mg 3\ 3 t 4
;9. y# LY !Hn$
- Status Epilepticus : IV : 5 t 10 mg 3\ 10
t 20 $ 34 )$ ("N>"\(G9X!=$ 30 mg B E:$ 8
;9. :8#E @Y G(#B E:$ 2 t 4 ;9. y# LY !Hn$

!

" #/ $
NSS, D5W
- IM, Direct IV G9X?#'>!L&'L >

(G9XAIb"9J" %D% E'&_$
!$&_'>L G9X!)# $ F?X' L
!?4E9K(Eb"9:$ NSS :$
AI 9!)#9)#$G9X!=$ 10 mg/
100 ml y# AI 9!)#9)#$"N>LD
??D'$F%Db"9:$)I(F#I
!3X $@$ G9XAIb"9:$ plastic
bags 8&' tubing G9XAI:;#
polyvinyl chloride (PVC)
plastics set $'L $4@ !L&'
L >LD3Y :8#E "N<!"4E
potency G(#!MI)
- IM
- Direct IV :$bN#:8<XLD:8#:$
'? !MIG9X!=$ 5 mg/ min
:$!(M 1 t 2 mg/ min y# :8#
3 >" E:8#" $@Y ?#'>:8#?>
?Y F8$X>:%#!)M934_?X':8#
bN#HpIE9 34_"\( !$&_'>L ' L
!=(H===E J" E:8#" $@Y
G(#F%D8%>L :8#E F%#IAI
flush (#IE NSS (2 - 5 mg/
$ 34 y# :8#!MI3Y :8#!=(
apnea hypotension,
bradycardia 8&' cadiac
arrest )
- )$ (:8#F?X%DA@>G9XAI!=$ 30 mg
- 8# 9b"9I9JE '&_$] !f DLD3Y :8#??D'$
- !L&'L > 1: 40 v/ v LD94AI 9A>?I 6 ;9.
- y# !L&'L > > 1: 50 A>?I 24 ;9.
- G9X$=E9:8# Infusion !$&_'>L ' L!=( ??D'$F%D
(N(JE L y\>E G(#
! : ?=(? 9I(D(JAI 9($X'$, D8IX >F%D8%>
:8#E , !=(8%'(!%&'((Y '!"J:$?Y F8$X>34_:8#E
X'$:8#E AII('? 8 E:Ly# ?_Y IX 12 A@>?X'$ 34 AI
FL#>:8#Ff3EC3 J 8%> :8#E 1 ;_IK9>AI?=(? 9I('?
8 E:L y# 8 G(#$#'EIX 8 A@>?X'$ 34:8#H%\bN#HpIE:8#94
'? 8 E:L!Hn$ 10 t 12 A@>?X'$ 34 y# G9X" 9 y3Y G(#
:8#;XIE8 E:L F%DFL#>:8#Ff3EC3 J
@A : CNS depression, respiratory depression 94
' "J"$ coma AI 9($K%8=??_Y fN(;#
- G9X:;#:$bN#HpIE Narrow angle glaucoma
- G9X:;#E NHFJJJHD3 $:$!(M' E\$#'EIX 6 !(&'$
- G9X:;#E NHFJJ}4(:$!(M' E\$#'EIX 30 I$
- G9X:;#:$"?494ABC
- USFDA Preg Cat D

Digoxin (Lanoxin)
0.5 mg/ 2 ml

/

/
- Antiarrthymic agent, B ID

Congestive heart failure F%D:;#!f&_'%(
'? !?#$)'>8I:L8#'>%X >:$B ID
atrial fibrillation, atrial flutter F%D
supraventricular tachycardia,
cardiogenic shock
Daily dose* (g/ kg)
Initial
Maintenance
Preterm infant
15 t 20
4t6
Full-term infant
20 t 30
6t8
1 !(&'$ t 2 H|
30 t 50
7.5 t 12
2 t 5 H|
25 t 35
8t9
5 t 10 H|
15 t 30
4t8
> 10 H|
8 t 12
2t3
bN#:8<X
500 t 1,000
100 t 400
* :$!(M' E\$#'EIX 10 H| FJX>:8#3\ 12 ;_IK9>
M

!
D5W, NSS, D10W, - G9X?#'>!L&'L >8&'!L&'L >E

SWFI
1 ml :$$@Y %_$8&'" %D% E
34_:;#G(#H=9 m 4 ml

" #/ $
- 'EX >$#'E 5 $ 34 :8#bX $

3 - way 8&' Y - site
- !9&_'!L&'L >F%#IAI:;#3$34
- :;#" %D% E!=$ 4 !3X ?IE LD??D'$
- !MJ34_'\m8BN9=G9X!=$ 25 '>a Hl'>$F">
- :8#E !)# 8%'(!%&'((Y 'EX >I(!MI!Hn$" !8?\:8#!=(
8(?I)'>8%'(!%&'( $Y GH"NXB IDAI 9($K%8=?"N>G(# F%D/
8&'%( G8%!I4E$)'>!%&'(:$!"#$!%&'(KAK$ 4_ }4(E
'EX >;# ] L~>!Hn$"=_>"Y A<:$bN#HpIE34_!=( hypertensive heart
failure F%D acute myocardial infarction
- :$bN#HpIE34_!Hn$KA!4_EIJ?X'9E'E(C?#'>:8#'EX >
D9(DI> AI%()$ (E !=_9?#$F%D)$ (?X'!$&_'>!9&_'

?X'9E'E(C3Y > $?_Y IX H?= :$bN#HpIE34_94
hyperthyroidism fJIX LD(&@'?X' digoxin ' L?#'>!f=9_
)$ (E )~@$D8IX >:8# f=)'>E'E(C
(thyrotoxicosis) AI%()$ (E %>!9&_'" 9 yAIJA\9B ID
f=(>%X IG(#F%#I
! : X'$:8#E F?X%DA@>:8#?=(? 9I(;4fL!Hn$!I%
1 $ 34 F%Dy# fJIX 94 !H%4_E$FH%> !;X$ !?#$G9X!Hn$L>8ID
H?=8&''? !?#$)'>8I:L?_Y IX 60 A@>?X'$ 348&'
9 IX 100 A@>?X'$ 34 !Hn$?#$ ~_>y# '? !?#$)'>8I:L
?_Y IX 60 A@>?X'$ 34LDJX>;4@IX !=(f=L E , BP, :$D8IX >
:8#E AI3Y ECG 'EX >?X'!$&_'> !f&_'?=(? 9 !=(
arrythmias ~_>y# !=(LDJX>J'IX !=(f=L E
Direct IV, IM (9HI( G9XAX'E:;#)
- USFDA Preg Cat C

/

/

!

" #/ $
Dobutamine
(Dobutrex)
250 mg/ 20
ml
- Sympathomimetic agents, :;#!f=_9

cardiac output DED"@$:$bN#HpIE34_94B ID
cardiac decompensate 34_94" !8?\L
KA8I:L, 8%> bX ?(8I:L8&' acute
myocardial infarction
- )$ ( :8#E :
Neonate : 2 t 15 g/ kg/ min
Children & Adult : 2.5 t 20 g/ kg/ min
HJ)$ (E L$G(#b%? 9?#'> K(E)$ (
E "N>"\(G9X!=$ 40 g/ kg/ min :8#E
?=(?X'$G9X$ $IX 72 ;_IK9>
D5W, D5S/2,
D5S, NSS,
RINGER
Dobutamine Lyophilized powder A@>F:8#b"9

J SWFI 8&' D5W LY $I$ 10 ml !)EX :8#%D% E
8 ?IE %D% EG9X89(:8#!f=_9!Hn$ 20 ml F%#I!)EX
L$%D% E!Hn$$@Y E :" !9&_'LDJ=8 E :8#bN#HpIE
?#'>!L&'L >(#IE IV Solution :8#G(#AI 9!)#9)#$
"N>"\(!3X J 5 mg/ml
- IV Infusion central line

8&' !"#$!%&'((Y :8<X F%D
AI:;# Infusion pump
AI%()$ (E %>;# ]
'EX >"9_Y !"9' F3$
8E\(}4('EX >3$343$:(
!f D' L!=( AI 9($
K%8=??_Y 3$343$:(
- 8%>%D% EF%#IA>?I 24 ;9. 34_'\m8BN9=8#'>

7$ :
- E 94"XI$HD'J)'> sulfites ~_>' L3Y :8#!=( allergic
reaction :$bN#HpIEJ > EG(#
- ' 34_!=()~@$!9&_')$ (E "N>!=$GH !;X$ tachycardia
8&' !H%4_E$FH%>)'>AI 9($K%8=?'EX >9 (>$@$
y# !=(' AI%D)$ (E %>8&'8E\(E L$' LD
A>34_
!: D(JKHF?"!4E9:$!%&'(, I(D(JAI 9
($K%8=?F%D'? !?#$)'>8I:L'EX >?X'!$&_'>
overdose: 'X'$!f%4E DI$DI E 8I:L!?#$
!MI AI 9($K%8=?"N> 8I:L!?#$G9X!Hn$L>8ID
-E
AI
-E
AI
-E
AI
250 mg !L&'L >:$" %D% E 1000 ml G(#

9!)#9)#$ 250 g/ ml
250 mg !L&'L >:$" %D% E 500 ml G(#
9!)#9)#$ 500 g/ ml
250 mg !L&'L >:$" %D% E 250 ml G(#
9!)#9)#$ 1000 g/ ml
" %D% E)'> dobutamine ' L!=("4;9fN ~_>LD

!)#9)~@$!&_'E] !9&'_ !I% bX $GH F?XG9X94b%?X'AI 9
F>)'>E 8 :;#:$;XI>!I% 34_DJ\GI#
IV Infusion
- USFDA Preg Cat B

Dopamine
250 mg/ 10 ml

/

/
- Sympathomimetic agents, :;#!f=_9 cardiac
output, blood pressure F%D urine flow !f&_'
;XIE B ID shock 8%>L :8#" $@Y
'EX >f'!f4E>F%#I
: 1 t 20 g/ kg/ min HJ)$ (E ? 9
?'J"$'>

: 1 t 20 g/ kg/ min HJ)$ (E ? 9
?'J"$'> )$ (E "N>"\( 50 mcg/ kg/ min
: 1 t 5 L$y~> 20 g/ kg/ min :$
HJ)$ (E LD!f=_9A@>%D 1 t 4 g/ kg/ min
3\ 10 t 30 $ 34L$G(# ?'J"$'>34_?#'>
)$ (E "N>"\( 50 g/ kg/ min
8 :;#)$ (E 9 IX 20 t 30 mcg/ kg/ min
' L:;# direct-acting pressor !;X$
epinephrine, norepinephrine F3$
Continuous IV Infusion S

infusion
pump " microdrip set $8

!
D5W, D5S/2, D ?#'>!L&'L >E X'$}4( :;#

5S, NSS, RINGER Dopamine 10 ml b"9
" %D% ELY $I$ 250 ml 8&'
500 ml :$m4bN#HpIELY ($@Y
8&' J=8 E 'EX >;# ]
" 9 y%D% EE :8#G(#AI 9
!)#9)#$ 1.6 8&' 3.2 mg/ ml
$@Y E 34_!L&'L >F%#I?#'>:;#:8#
89(B E:$ 24 ;9. Hl'>$
F"> $@Y E 34_!L&'L >LD94"4
!8%&'>L >] 8 $@Y E 94"4
!H%4_E$GH 8&'"4!)#9)~@$ G9XAI
:;#
(%D% E?IE 200 - 400 mg
:$" %D% E34_:;#G(# 250 500 ml)

" #/ $
- Shock: :8#!=_9?#$
2 - 5 g/ kg/ min F%#IHJ
? 9 ?'J"$'>)'>bN#HpIE
- CHF : :8#!=_9?#$
0.5 - 2 g/ kg/ min
F%#IHJ? 9 ?'J"$'>
)'>bN#HpIE
- :8# IV Infusion central line 8&' !"#$!%&'((Y :8<X F%D AI

:;# Infusion pump AI%()$ (E %>;# ] 'EX >"9_Y !"9'
F3$ 8E\(}4('EX >3$343$:( !f D' L!=( AI 9($K%8=?
?_Y 3$343$:(
- E 34_!)# $G(# : Dobutamine, epinephrine, isoproterenol,
lidocaine
7$ : DI> _I''$'!"#$!%&'(!$&_'>L LD3Y :8#
!=( gangrene
- !9&_'LD8E\(E :8#AX'E ] %('? !MI)'> :8#E !f&_'Hl'>$
!=( hypotension 'EX >\$F>
- :8#E :$)$ ("N>LD!f=_9 renal vasoconstriction F%D
peripheral resistance
- X'$:8#E dopamine AIHJB ID hypovolumia X'$
E 94"XI$b"9)'> sulfites ' L3Y :8#!=( Ff#E G(#
- 8%>%D% EF%#IA>?I 24 ;9. 34_'\m8BN9=8#'> (y# "4!)#9)~@$:8#
3=@>GH)
! : X'$F%DD8IX >:8#E AI?=(? 9 heart rate,
blood pressure, urine output, cardiac output, central
venous pressure, peripheral perfusion
overdose : AI 9($K%8=?"N> 8I:L!?#$G9X!Hn$L>8ID
G?I E!}4EJf%$
- USFDA Preg Cat C

Diphenhydramine
(Benadryl)
50 mg/ ml
Ephedrine sulfate
50 mg/ ml,
10 ml

/

/
- Antidote, Antihistamine

: IM ; 1.25 mg/ kg 8&' 37.5 mg/ m2 )'>
f&@$34_X > E :8#I$%D 4 A@> )$ ( :8#E
"N>"\(G9X!=$ 300 mg/ day
: IM, IV ; 10 t 50 mg )$ ( :8#E
"N>"\(G9X!=$ 100 mg/ dose F%D 400 mg/ day
- B ID Dystonic reaction

: IM, IV ; 0.5 t 1 mg/ kg/ dose
: IM, IV ; 10 t 50 mg single dose :8#
@Y 3\ 2 t 4 ;9. "N>"\(G9X!=$ 400 mg/ day
IM, IV Infusion, Intermittent IV
- Sympathomimetic agents, Alpha t Beta
agonist
- B ID Idiopathic orthostatic
hypotension, acute bronchospasm

: IM, IV Push ; 0.2 t 0.3 mg/ kg/ dose
3\ 4 t 6 ;9.
: IM, SC ; 25 t 50 mg )$ ("N>"\(G9X
!=$ 150 mg/ day
IV : 5 t 25 mg/ dose slow IV push @Y G(#'4 5
t 10 $ 34 y# LY !Hn$" 9 y:8#G(#3\ 3 t 4 ;9.
IM, SC, Direct IV

!
NSS, D5W, D10W, !L&'L >:$" %D% E34_:;#G(#:$

NSS, RINGER
AI 9!)#9)#$ 100 mg/ L
G9X?#'>!L&'L >' L:8#bX $

Y - tube 8&' three way
stopcock

Direct IV : 25 mg 'EX >$#'E
1 $ 34
- IM, SC, slow IV push G9X

?#'>!L&'L >E X'$}4( K(E
slow IV push :$bN#:8<X }4(
@Y 8X >$ 5 t 10 $ 34 y#
LY !Hn$ :8#?X'GH3\ 3 - 4 ;9.
F?XG9X!=$ 150 mg/ day
)$ (E :$!(MG9X!=$ 3 mg/
kg/ day
" #/ $
- ">!?' Ff#!;X$b&_$A$, %9f=, 8 E:L3$34?=()(,
AI 9($?_Y
- 8# 9:;#:$ New Born F%D Premature infant
- Hl'>$F">
(Onset : 20 t 30 $ 34, Duration : 6 t 8 ;9. )
- USFDA Preg Cat B

- 8 " %D% E)\X$8&'94?D'$G9XAI$Y 9 :;#
- !MJE 34_'\m8BN9=8#'>:8#f#$F">
7$ :
- :8#HJB ID hypovolumia X'$:8#E
! : AI 9($K%8=?, ;4fL F%D urine output
overdose : dysrythmias, CNS excitation (
8 E:L ~9!a# ' !L4E$ ; !=( overdose ' L3Y :8#!=(
CV collapse :8#F#G)? 9' 34_!=()~@$ G9X94 antidote 34_
LY !f D!L DL>
- USFDA Preg Cat C

Epoetin Alfa
(Eprex)
2,000 u/ ml, 1 ml
3,000 u/ ml, 1 ml
4,000 u/ ml, 1 ml

/

/

!
- Colony - Stimulating Factor, anemia

34_94AI 9"9f$CJ :;# AZT HIV
infection, B ID CHF, bN#HpIE34_G(#J bX ?(
F%#I94 Allogenic blood transfusion %(%>.
- CHF patient : IV, SC ; )$ ( :;#E (>:$
?>
G9X?#'>!L&'L >
Initial
!(M
50 u/ kg
3 times/
week
bN#:8<X
50 t 100
u/ kg
3 times/
week
Maintenance
Dialysis
167 u/ kg/
week 8&'
76 u/ kg
2 t 3 times/
week
75 u/ kg
3 times/
week
No dialysis
50 t 250 u/
kg
1 t 3 times/
week

Direct IV : 1 $ 34
" #/ $
- B ;$D single dose (1 ml) A>?I 2 ' 3=?EC
34_'\m8BN9=8#'> (E!I#$)$ ( 4000 u/ ml A>?I 1 ' 3=?EC)
- B ;$D multiple dose (2 ml) A>?I 1 ' 3=?EC34_'\m8BN9=8#'>
- DI> :;#:$bN#HpIE34_Ff#'%JN9=$ F%DbN#HpIE34_AIJA\9AI 9
($K%8=?:8#'ENX:$D(JH?=G9XG(#
7 : AI 9($K%8=?"N>, HI(a4D, A%&_$G"#, G9X94F>,
JI9, !LMJ8$# ', 3#'>!"4E
- AI!MJE GI#34_'\m8BN9= 2 t 8 '>a !%!4E"
- 8# 9!MJ:$;X'>F;XF)M>
- 8# 9!)EX )I(
75 t 120 u/
kg
- Surgery patient : X'$:8#?#'>!L D!%&'((N

D(J HB IX 9 IX 10 mg/ dl 8&'$#'EIX
13 mg/ dl
Adult : SC ; !=_9:8# 300 u/ kg/ day X'$bX ?(
10 I$, I$34_bX ?( F%D8%>L bX ?('4 4 I$
Direct IV, SC
- USFDA Preg Cat C

/

/

!
- Hl'>$F%D thromoembolic disorders

Enoxaparin
Hl'>$B ID8%'(!%&'((Y ?4J (Venous thromboembolic disease) :$bN#HpIEa%E9
injection
60 mg/ 0.6 ml =< >6
Hip replacement :
- 30 mg I$%D 2 A@> K(E:8#E A@>F8%> bX ?( 12 t 24 ;9. 8%>L $@$:8#E ?X'L$D3_>bN#HpIEG9X94AI 9!"4_E>?X'
80 mg/ 0.8 ml
!=( DVT 8&'!9&_' warfarin :8#b% K(E!}%4_ELD:8#E $ $HD9 m 7 t 10 I$
- 40 mg I$%DA@> K(E:8#E A@>FX'$ bX ?( 9 t 15 ;9. 8%>L $@$:8#E ?X'L$D3_> bN#HpIEG9X94AI 9!"4_E>?X' !=(
890
DVT 8&'!9&_' warfarin :8#b% 8 bN#HpIEG9XG(#JE warfarin ' L?#'>:8#E I$%DA@>?X''4 3 "H( 8C (I9!Hn$ 4
$/
"H( 8C)
:0
<=>6
Knee replacement :
$;:0
- 30 mg I$%D 2 A@> K(E:8#E A@>F8%> bX ?( 12 t 24 ;9. 8%>L $@$:8#E ?X'L$D3_>bN#HpIEG9X94AI 9!"4_E>?X'
!=( DVT 8&'!9&_' warfarin :8#b% K(E!}%4_ELD:8#E $ $HD9 m 7 t 10 I$ maximum course 14 I$
- :$bN#HpIE34_$@Y 8$$#'EIX 45 kg 8&'' E\9 IX 65 H| ' L:8#E :$)$ ( 0.5 mg/ kg/ dose 3\ 12 ;9. !f&_'%(AI 9
!"4_E> !=(B ID!%&'(''
<=>6
CDD :
- :8#E )$ ( 40 mg I$%DA@> :8#E A@>FX'$ bX ?( 2 ;9. DED!I% :8#E !}%4_E 7 t 10 I$ "N>"\( 12 I$
- Acute proximal DVT : :8# warfarin B E:$ 72 ;9. F%D:8# enoxaparin XI9$L$G(#AX INR 2.0 - 3.0 (HD9 m 7 I$)
<= DVT HIJHKJJHL= pulmonary embolism : SC 1 mg/ kg/ dose 3\ 12 ;9. 8&' 1.5 mg/ kg I$%DA@>
- "Y 8JHl'>$B ID8I:L) (!%&'(:$bN#HpIE unstable angina 8&' non-Q wave MI : SC : 1 mg/ kg/ dose I$%D 2 A@> K(E:8#
XI9J aspirin 100 t 325 mg/ day :8#'EX >$#'E 2 I$L$bN#HpIE94' 3 >A%=$=(4)~@$
- Hl'>$ !=(%=_9!%&'(:$)mD%# >G?(#IE!A&_'>G?!34E9 : :8#E )$ ( 1 mg/ kg 8 bN#HpIE94AI 9!"4_E>"N>?X' !=(!%&'(''
AI%()$ (E %>!Hn$ 0.5 mg/ kg F%DAI:8#E bX $3 > arterial line :$;XI>?#$)'>DJI$ %# >G? HD"=3=B f)'>E LD'ENXG(#
$ $ 4 ;9. 'EX >GM? 98 94 fibrin !=()~@$ ' L:8#E !f=_9G(#'4!Hn$ 0.5 t 1 mg/ kg
O56P <=HIJHL=5DQDK>PRD bN#HpIE34_94 creatinine clearance < 30 ml/ min :8#E )$ ( 1 mg/ kg/ day :8#I$%D
A@>"Y 8J 8&' 20 mg/ day "Y 8JHl'>$

" #/ $
- :8#K(E }4(!)# :?#b=I8$> 890$/
:0$;:0
- !9&_'94 3Y Epidural/ spinal anesthesia XI9J :;#
E Enoxaparin :"XF%D y'( catheter AI3Y !9&_'
3=?# $ F)M>?I)'>!%&'('ENX:$D(J?_Y F%#I 8&'3Y
8%>L G(#JE )$ ( 40 mg/ I$ 8&'?_Y IX GHF%#I 10 t
12 ;9. 8&'8%>L G(#JE )$ ("N> (1mg/ kg I$%D 2
A@>8&' 1.5 mg/ kg I$%DA@>) GHF%#I 24 ;9. 8
LY !Hn$?#'>:8# enoxaparin '4 AI3=@>;XI>8X >G9X$#'EIX 2
;9. 8%>y'( catheter '' LY !Hn$?#'>94 ?=(? 9"B ID
)'>bN#HpIE3 >DJJHD" 3'EX >:%#;=( 8 ">"EIX 94
neuroxial hematoma !=()~@$?#'>4JI=$=L}EF%D:8#
XI9J 3Y spinal cord decompression
- AID9(DI> :;#E :$bN#HpIE34_'ENX:$"B ID!"4_E>?X'
!=(!%&'('' !;X$ bN#HpIE34_94 F)M>?I)'>!%&'(b=(H?=, 94
HDI?=Fb%:$D!f D' 8 , 94HDI?=!%&'('':$"9'>,
AI 9($K%8=?"N>\$F>G9X" 9 yAIJA\9G(#, KA!J 8I $
34_94' retinopathy !Hn$?#$
! : ?IL$J!M(!%&'(, 8 occult blood 8&'
B ID!%&'(''b=(H?='&_$] 8 !M(!%&'(%(%>?_Y IX 30 50 % )'>AX !=_9?#$ :8#8E\(E , G9XLY !Hn$?#'>?IL8 AX PT
8&' PTT
overdose : 94!%&'(''b=(H?=
- USFDA Preg Cat B

Estrogen
Conjugated
25 mg/ 5 ml
5 - Fluorouracil
(5 - FU)
250 mg/ 5 ml
Furosemide
(Lasix)
20mg/ 2 ml

/

/
- Estrogen derivatives
- Abnormal uterine bleeding : IM, IV ; 25 mg y#
LY !Hn$' L:8#@Y G(#3\ 6 t 12 ;9.
- Uremic bleeding : IV ; 0.6 mg/ kg/ day !Hn$
DED!I% 5 I$
IV, IM
- Antineoplastic agent
- 12 mg/ kg/ day !I% 4 I$? 9(#IE
6 mg/ kg/ day '4 4 I$
Direct IV, Intermittent IV
- Diuretic, Loop
- :;# B IDJI9L CHF, HTN, KA?J F%DG?
Infant & Children : IM, IV ; 1 mg/ kg/ dose !f=_9
)$ (E )~@$G(#A@>%D 1 mg/ kg/ dose :8#E 3\ 6 t
12 ;9.
Adult : IM, IV ; 20 t 40 mg/ dose :8#E 3\ 6 t 12
;9. K(E3_IGH"Y 8J Acute pulmonary edema :;#
)$ ( 40 mg IV :8#$ $IX 2 $ 34 y# G9Xf'
" 9 y!f=_9)$ (E G(#y~> 80 mg
Continuous IV infusion ; !=_9(#IE IV bolus 0.1
mg/ kg ? 9(#IE IV infusion 0.1 mg/ kg/ hr !f=_9
)$ (E G(#'4!3X ?I3\ 2 ;9. )$ ("N>"\(G9X!=$
0.4 mg/ kg/ hr
IM. Direct IV, IV infusion

!

Sterile diluent, %D% Eb>E :$" %D% E34_:;#G(#
WFI, NSS,
!)EX b"9$!J
Dextrose
$/% <!
NSS, D5W
NSS, D5S,
D5W, D10W ,
RINGER, 3 %
NaCI
- Direct IV : G9X?#'>!L&'L >8&'!L&'

L >" %D% E34_:;#G(# (:8#bX $" E
IV !f&_'%(AI 9!LMJHI()
- Infusion : !L&'L >
- Direct IV, IM : G9X?#'>!L&'L >
- Infusion : !L&'L >(#IE" %D% E
34_:;#G(#

" #/ $
IV Direct }4(;# ]
- 8 }4(3 > IV AI}4(;# ] !f&_'Hl'>$ !=( Flushing

- 8# 9:;#:$bN#HpIE34_Ff#E
- :8#bN#HpIEJHD3 $ Vit D F%D Calcium 'EX >!f4E>f'
- 8# 9!)EX )I(E F> y# "4!)#9)~@$:8#3=@>GH
- 8%>!H(AI!MJ:$?N#!EM$ K(E!MJG(#G9X!=$ 60 I$
- USFDA Preg Cat X
- Direct IV : 1 - 2 $ 34 - !L&'L >F%#IA>?I 24 ;9. 34_'\m8BN9=8#'> b"9E ? 9F$I3 >
- Intermittent IV : 2 - 8 !?4E9E !A94JY J(:$ Biohazard laminar flow 34_G(#
;9. y# :8#!MILD3Y :8#!=( 9 ? $!f D' L!=('$? EJbN#!?4E9E G(#
f=
- USFDA Preg Cat X
- Direct IV : 20 mg/ 1 - - !9&_'!L&'L >F%#IAI:;#B E:$ 24 ;9. 8 " %D% E% E
2 $ 34
!Hn$"4!8%&'>:8#3=@>3$34
- IV Infusion : G9X
- y# :"X?N#!EM$LD??D'$ 3=@>GI#34_'\m8BN9=8#'>F%#I" 9 y$Y
9 IX 4 mg/ $ 34
%J9 :;#G(#'4
)$ (E !f=_9!?=9:
- Refractory HF : IV ; 8 g/ day
- Elderly : IM, IV ; 20 mg/ day
- USFDA Preg Cat C,D if used in preg induced

hypertension

Fentanyl injection
0.05 mg/ ml

/

/
- :;#!Hn$E ">JD>JHD" 3X'$ bX ?(8&'3Y
8?y )$ (!%M, :;#D>JHI(

1 12 :
- :;#">JHD" 3:$ 3Y 8?y )$ (!%M/
J!3 HI( : IM, IV : 1 t 2 g/ kg/ dose ' L:8#
@Y G(#:$DED!I% 30 t 60 $ 34 !(M' E\ 18 t 36
!(&'$ ' L:;# 2 t 3 mg/ kg/ dose
- A>"B f">JHD" 3 : !=_9 IV bolus : 1 t 2 g/
kg F%#I:8# 1 t 3 g/ kg/ hr L$G(#)$ ("N>"\(A&' 5
g/ kg/ hr

J= 12 :
- :;#">JHD" 3:$ 3Y 8?y )$ (!%M/
J!3 HI( : IV : 25 t 50 g :8#E @Y G(#3\ 3 t 5
$ 34L$G(# ?'J"$'>34_?#'> )$ (E "N>"\(G9X
!=$ 500 g/ 4 hr
- :;#">JHD" 3X'$ bX ?( 8&':;#XI9JE ;
!}f D34_8&'J!3 ' HI(8%>bX ?( : IM,
Slow IV : 25 t 100 g/ dose X'$bX ?( 30 $ 34
- :;#XI9JE ; 3_IGH : Slow IV :
Low dose : 0.5 t 2 g/ kg/ hr
Moderate dose : !=_9?#$ 2 t 15 g/ kg/ dose :8#
?X':$)$ ( 1 t 2 g/ kg/ hr
High dose (rare use) : 20 t 50 g/ kg/ hr

!

SWFI, NSS, - IM G9X?#'>!L&'L >
D5W
E
- Direct IV: y# :8#
K(EI="<<4Ff3EC
' LG9X?#'>!L&'L >
E 8&'' L!L&'L >
(#IE sterile water
8&' NSS 'EX >
$#'E 5 ml
- Continuous IV
Infusion : !L&'L >
E (#IE 250 ml
)'> D5W

" #/ $
- IM
- Direct IV : :$bN#:8<X:8#" %D% E34_!L&'L >
F%#I 0.1 mg :8#!I% 1 t 2 $ 34
y# )$ (E "N> (> 5 mcg/ kg) ' L:;#!I%
5 t 10 $ 34
:;#:$!(M:;#)$ ( 1 t 2 mcg/ kg/ dose
K(E:;#!I% :8#E $ $ 3 t 5 $ 34
- Continuous IV infusion : J >A@>LD:;#;
$Y "%JF%DD>J' HI( '? !MI)'>
:8#E LDHJ? 9)$ (E 34_?#'> F%D
?'J"$'>)'>bN#HpIE
!(M' E\D8IX > 1 t 12 H| LD!=_9:8#:$'? !MI
1 mcg/ kg/ hr F%DHJ)$ (E L$G(#b%? 934_
?#'> K(E)$ (E "N>"\(!3X J 3 mcg/ kg/
hr
!(M' E\$#'EIX 1 H| !=_9:8#:$'? !MI
0.5 t 1 mcg/ kg/ hr
- y# :8#:$'? 34_;# !=$GH' L3Y :8#!=(!f#'A%_> DI$

DI EXI9J94 laryngospasm y# :8#:$'? 34_!MI!=$GH
LD3Y :8#!=( !M>?I)'> chest wall F%D%# 9!$&@'% E
3Y :8#EJE@> F%!H%4_E$''=!L$94b%3Y :8#!=( 8E\(
8 E:LG(#
E$A : Hl'>$F"> '\m8BN9= 15 t 30 C
- !9&_':;#E :$)$ ("N>LD94b%( 8 E:L$ $!Hn$!I%
8% E;9. 8%>$L "%JG(# 8 !=(B ID$4@AI
;XIE!8%&' 8 E:L
- :$bN#HpIE34_G(#J)$ (E @Y 8&'94B ID(&@'?X'E %\X9
opioids ' L!=( (&@'?X' fentanyl G(#
- E ' L3Y :8#!=( !M>?I)'> chest wall 94b%EJE@>
F%!H%4_E$''=!L$"X>b%?X'DJJ8 E:L ~_>' L!=(G(#
L ;$Y "%J
- 8%>L bN#HpIE$L "%J' LLD!=( delayed
respiratory depression, respiratory arrest, bradycardia,
asystole arrythmias F%D hypotension
y# !=(B ID Overdose AI:8# FJJ supportive
L$IX E LDyN metabolized 89( (half life 2 - 4 ;9.)
- reverse B ID respiratory depression AI:8#
naloxone 2 mg IV (0.01 mg/ kg :$!(M) :8#@Y G(#L$G(#
)$ (E I9G9X!=$ 10 mg
- USFDA Preg Cat C; D if prolonged use/high doses at
term
UV:
- IM; onset 7 t 15 $ 34 DED!I% 1 - 2 ;9.
- IV; onset 3$34 DED!I% 0.5 - 1 ;9.

Gentamicin
80 mg/ 2 ml
Haloperidol lactate
(Haldol)
5 mg/ ml, 1 ml
Haloperidol
Decanoate
(Haldol decanoas)
50 mg/ml, 1 ml

/

/

- Antibiotic, Aminoglycoside
- )$ ( :8#E : IM, IV ; 2 t 2.5 mg/ kg/ dose
3\ 8 t 12 ;9.
- Hl'>$ bacterial endocarditis : 1.5 mg/ kg
(max 80 mg) XI9J Ampicillin 50 mg/ kg (max
2 g) X'$3Y 8?y 30 $ 34
IM,IV Infusion
- Antipsychotic agent, sedative
-
6 12 : IM ; 1 t 3 mg/ dose 3\ 4 t
8 ;9. )$ ("N>"\(G9X!=$ 0.15 mg/ kg/ day
- : Psychosis: IM ; 2 t 5 mg 3\ 4 t 8 ;9.
- bN#:8<X : Psychosis : 50 t 100 mg 3\ 4 "H( 8C
NSS, D5W,
RINGER
- Infusion : 1 amp :$
" %D% E34_:;#G(#'EX >$#
'E
50 - 200 ml
NSS, D5W
- Direct IV : G9X?#'>!L&'L > - Direct IV : 5 mg/ $ 34

- Infusion : !L&'L >?X':$ - IV Infusion : 'EX >$#'E
" %D% E34_:;#G(#
30 $ 34
IM $ % &
!

" #/ $
1 .5 - 2 ;9. !f&_'3Y :8#E 94

3=:$ X !;&@'E I)~@$
- 8%>b"9!f&_':8# IV Infusion F%#I AI:;#B E:$ 24 ;9.

- E 8%>!H(:;#F%#I94AI 9A>?I 30 I$
- G9XF$D$Y :8#!MJ:$?N#!EM$
- :8#!MI!=$GH:$)$ ( > 100 mg LD3Y :8# hearing loss
G(#
- AI:8#E H=;4I$D'&_$8%> genta 'EX >$#'E 1 ;9.
- USFDA Preg Cat C
- !9&_'!L&'L >F%#IA>?I 24 ;9. 34_'\m8BN9=8#'>:"X:$B ;$D
Hl'>$F">
- AI:8#3 > IM
- USFDA Preg Cat C
- 8# 9:8#3 > IV
- USFDA Preg Cat C

Hydrocortlsone
Sodium succinate
(Solu - Cortef)
100 mg ; powder

/

/
- Glucocorticoid, Mineralocorticoid
- Acute adrenal insufficiency : IM, IV ;
Infant & young children : 1 t 2 mg/ kg 8%>L
$@$:8# 25 t 150 mg/ day FJX>:8#3\ 6 t 8 ;9.

T> : 1 t 2 mg/ kg 8%>L $@$:8# 150 t 250
mg/ day FJX>:8#3\ 6 t 8 ;9.
: 100 mg IV bolus 8%>L $@$:8# 300 mg/
day FJX>:8#3\ 8 ;9. 8&':8# IV continuous
infusion $ $ 48 ;9.
- Inflammation : IM, IV ;

: 1 t 5 mg/ kg/ day FJX>:8#3\ 12 t 24 ;9.
: 15 t 240 mg 3\ 12 ;9.
- Shock: IM, IV ;

: 50 mg/ kg 8%>L $@$ 4 ;9. :8#E '4 1 A@>
F%D/ 8&' :8#8%>L $@$ 24 ;9. '4A@>8$~_>
: 500 mg t 2 g 3\ 2 t 6 ;9.

!
D5S/2, D5S, NSS, - Direct IV, IM : %D% E(#

D5W, D10W,
IE$@Y %_$, NSS 2 ml
RINGER
- IV Infusion : !L&'L >(#IE
" %D% E34_:;#G(# 100 ml
!f&_':8#G(#AI 9!)#9)#$ 1
mg/ ml

- IM, Direct IV :
100 mg/ 30 I=$ 34
- IV infusion : J=8 E $ $
IX 20 $ 34
" #/ $
- !9&_'%D% EF%D!L&'L >F%#IA>?I 3 I$34_'\m8BN9=8#'>
! : Serum glucose, BP, Weight, electrolytes
- USFDA Preg CatC: D in first trimester

/

/

D5W, NSS
Heparin injection - Hl'>$F%D thromoembolic
disorders

:
- Intermittent IV !=_9?#$(#IE)$ ( 50 t 100
units/kg ?X'L $@$:8# 50 t 100 units 3\
4 ;9
- IV Infusion !=_9?#$(#IE)$ ( 50 units/ kg
?X'L $@$:8# 15 t 25 units/ kg/ hr 8
LY !Hn$:8#!f=_9)$ (A@>%D 2 t 4 units/ kg/ hr
3\ 6 t 8 ;9. ? 9LY !Hn$
:
- Intermittent IV !=_9?#$(#IE)$ ( 10,000
units ?X'L $@$:8# 50 t 70 units/ kg (5,000
t 10,000 units) 3\ 4 t 6 ;9.
- IV Infusion !=_9?#$(#IE)$ ( 50 units/ kg
?X'L $@$:8# 15 t 25 units/ kg/ hr K(E:8#
FJJ continuous infusion !f=_9)$ (A@>%D
5 units/ kg/ hr 3\ 4 ;9.
Direct IV, Intermittent IV, IV Infusion
!
- Intermittent IV Injection ' L
G9X?#'>!L&'L >E 8&'!L&'L >
(#IE NSS 50 - 100 ml
- IV infusion : standard
diluents : D5W :$'? "XI$
25,000 unit/ 500 ml )'>
D5W
IM

- Direct IV : :;#A@>FK(E:8#bX $" E
:8#" $@Y 34_!)# $G(# K(E:8# 5000 units
:;#!I% 1 $ 34 :$!(M:;#)$ ( 50 units/
kg :$!I% 9 IX 1 $ 34
- Intermittent IV Infusion : :8#E 34_G9XG(#
!L&'L >8&'!L&'L >:$ 50 t 100 ml NSS
bX $3 > infusion pump
- Continuous IV Infusion : :;# infusion
pump :$!I% 24 ;9. K(E3_IGHLD:8#
:$'? !MI 1000 units/ ;9. F?X)~@$J
)$ (E 34_?#'>
- Subcutaneous : :;#J :8# heparin
FJJ fixed low-dose ()$ (E 5000 t
7500 unit 3\ 12 ;9. ) G9XLY !Hn$?#'>
!L&'L >E
" #/ $
- }4(E :8#}4(FJJ intrafat 8&' deep subcutaneous
AI}4(J=!Im abdominal fat layer 8X >L "D(&'9 IX 2
$=@I 8%>}4(:8#(J=!Im34_}4(!J ] 5 - 10 I=$ 34 8# 9$I(
J=!Im34_}4(F%D!H%4_E$34_}4(A@>?X'GH!f&_'Hl'>$ !=(
hematoma
- " %D% E34_!L&'L >F%#I94AI 9A>?I 24 ;9.
- " %D% E34_E>G9XG(#!L&'L >8%>!H(:;#94AI 9A>?I 30 I$
- 8# 9:8#E K(EI=4 IM !$&_'>L LD3Y :8#DA E!A&'> HI(
J=!Im34_}4( (Hematoma)
- ' )'> G(#E !=$)$ (A&' B ID!%&'('' K(EE
?# $f=A&' Protamine sulfate 1 mg ?X' heparin 100 units
F%D8E\( :8#E heparin y# 94 Progressive immune
thrombocytopenia !=()~@$
!: Platelet counts, aPTT, hemoglobin,
hematocrit, sign of bleeding, ?IL'\LL D8 occult
blood
- AI?ILAX aPTT X'$ :8# heparin F%D?IL?=(? 9
!9&_':8#E GHF%#I 6 - 8 ;9. 8&'8%>L 94 HJ)$ (E 6 8 ;9. K(E3_IGH aPTT 34_:8#b% AI'ENXD8IX > 1.5
t 2.5 !3X )'>AX H?= (AX aPTT )'>bN#HpIEX'$:;#E )
- USFDA Preg CatC

/

/

Hyoscine t N Butylbromide (Kanin

injection) 20 mg/ ml
Imipenem +
Cilastatin (Tienam)
500 mg + 500 mg
- Antispasmodic Agent : 1 - 2 amp,

Max : 5 amp daily
SC, IM, slow IV
- Antibiotic, Anaerobic, Carbapenam
- )$ ( :8#E 250 mg - 1000 mg 3\
6 - 8 ;9. )~@$JAI 9\$F>)'> ?=(!;&@'
Sterile water for

Injection (SWFI)
Insulin, regular
(RI)
100 unit/ 10 ml
Intermittent IV, not for Direct infusion

- Antidiabetic agent
- Dose LDHJ? 9D(J$@Y ? %
:$!%&'(
IM, SC, Direct IV, Infusion
!
Direct IV : !L&'L >(#IE
SWFI 35 ml
D5W, D10W, NSS, - b"9E 500 mg J

Ringer, NSS/2
" %D% E34_:;#G(#10 ml F%#I
!L&'L >?X''EX >$#'E 100 ml
- b"9E 1 g J" %D% E
250 ml (NSS)
0.45 % NaCI, NSS - Direct IV : G9X?#'>!L&'L >

}4(!)# 3 > 3 - way
- IV Infusion : !L&'L >:$
" %D% E34_:;#G(#:8#G(#
100 u/ 100 ml

Direct IV :8#;# :$ 1 $ 34
- 500 mg :8#$ $ 20 - 30
$ 34
- 1 g :8#$ $IX 40 t 60
$ 34 (AI 9!)#9)#$"N>"\(G9X
AI!=$ 5 mg/ ml)
50 EN$=?/ $ 34
" #/ $
- DI> :;#:$bN#HpIEKA8I:LLD3Y :8#!=( Tachycardia
- y# !Hn$E !9M(FJJ release form 8# 9J(8&'!A4@EI
- USFDA Preg CatC
- 8 bN#HpIE!=(A%&_$G"#' !L4E$AI%('? !MI:$ :8#%>
DI> anaphylaxis :$ :8#E A@>F
- 8%>%D% EF%#I(#IE" %D% E34_:;#G(#A>?I 4 ;9.34_
'\m8BN9=8#'> F%D 24 ;9. 34_'\m8BN9= 4 '>a !%!4E"
(E!I#$:;# NSS 'ENX$ $)~@$ 10 ;9.
34_'\m8BN9=8#'> F%D 48 ;934_ 4 '>a !%!4E"
- USFDA Preg CatC
- " 9 y!MJ34_'\m8BN9=8#'>G9X!=$ 37 '>a !%!4E" $ $ 1
!(&'$
- :8#3 > IV LD:;#G(#!}f D Regular insulin !3X $@$
- USFDA Preg CatC E!I#$ Lispro Preg Cat B

Ketamine
(ketalar)
50 mg/ ml, 10 ml
(500 mg/ 10 ml)

/

/

!
- General anethetic, :;#;$Y "%J

:$ bX ?()$ (!%M
)$ (E !=_9?#$"Y 8J;$Y "%J

:
- IM : 3 t 7 mg/ kg
- IV : ;XI>)$ ( :;#E H?=A&' 0.5
t 2 mg/ kg "Y 8J!8$4_EI$Y "%J
!f&_'3Y 8?y !%M$#'E:;#)$ ( 0.5 t
1 mg/ kg "Y 8J!8$4_EI$Y "%J
3_IGH:;#)$ ( 1 t 2 mg/ kg
maintained (#IE)$ ( 1/ 3 t 1/ 2 )'>
)$ (!=_9?#$
:
- IM : 3 t 8 mg/ kg
- IV : : ;XI>)$ ( :;#E H?=A&' 1 t
4.5 mg/ kg "Y 8J!8$4_EI$Y "%J
3_IGH:;#)$ ( 1 t 2 mg/ kg
maintained (#IE)$ ( 1/ 3 t 1/ 2 )'>
)$ (!=_9?#$
D5W, NSS, SWFI
- Direct IV : !L&'L >:8#G(#

1 mg/ ml (1 amp :$
" %D% E 500 ml)
" %D% E34_:;#G(# 500 8&'
250 ml (1 t 2 mg/ ml)
IM, IV, Continuous IV Infusion
(E }4( IV " 9 y!L&'L >

(#IE" %D% E F%DAI 9
!)#9)#$"\(3# EG9X!=$
2 mg/ ml)

- IM, Direct IV : :8#;# ]
'EX >$#'E1 $ 34
- IV Infusion: '? :8#E
0.5 mg/ kg/ min
(G9XF$D$Y :8#E FJJ
Intermittent infusion)
" #/ 7$
- !MJE :8#f#$F"> 8# 9:;#8 E !=(??D'$
- G9X!)# $J Barbiturate 8&' Diazepam LD??D'$
UV: 8%>L :8#E single dose
Anesthesia: IM 12 - 25 $ 34 IV 5 - 10 $ 34
Analgesia: IM 15 - 30 $ 34
Amnesia: 'ENXD8IX > 1 - 2 ;9.
Recovery: IM 3 - 4 ;9. IV 1 - 2 ;9.
7$ :
- Ketamine LD3Y H==E K(E?>J Barbiturates
!f D}D$@$G9XAI:8#E 3@>"'>K(E :;# Syringe XI9$
- !$&_'>L ketamine LD94b%3Y :8#!=(' !L4E$G(# (>$@$!f&_'
Hl'>$ "Y %!)# H'(L~>AI:8#E FXbN#HpIE!9&_'3#'>IX >
- :8#E )$ ("N>!=$GH8&'!MI!=$GHLD3Y :8#!=( respiratory
depression, apnea, hypertension
!: Cardiovascular effects, heart rate, blood
pressure, respiratory rate, transcutaneous O2 saturation :$
bN#HpIEAI 9($K%8=?"N>8&'KA8I:LAI?=(? 9 ECG D8IX >
:8#E (#IE
- overdose : 8 E:LyN( ' L!f=_9AI 9($K%8=?F%D'?
!?#$)'>8I:L F?X:$J > E' L!=(?>)# 9
- E: !MJ$F"> F%D34_'\m8BN9=G9X!=$ 8 - 15 OC
- USFDA Preg Cat D

Lignocaine
injection
(Xylocard)

/

/

!

" #/7$
- :;# B ID ventricular arrhythmias L

myocardial infarction, cardiac
manipulation, digitalis intoxication !Hn$
drug of choice :$ ventricular
ectopy, ventricular tachycardia,
ventricular fibrillation

:
- Endotracheal, intraosseous, IV : Loading
dose 1 mg/ kg " 9 y:8#@Y G(#'4:$!I%
10 t 15 $ 34'4 2 A@> 8%>L :8# loading
dose F%#I!=_9:8# IV continuous :$'? !MI
20 t 50 mcg/ kg/ min bN#HpIE CHF ?#'>
%()$ (E %>
:
- Antiarrythmias : Loading dose
1 t 1.5 mg/ kg K(E IV bolus 2 t 3 $ 34 :8#
@Y G(#:$)$ ( 0.5 t 0.75 mg/ kg
:$ 5 t 10 $ 34 L$G(#)$ (I93@>89(!3X J
3 mg/ kg
Continuous infusion 1 t 4 mg/ min
- Ventricular fibrillation : !=_9(#IE)$ (
1.5 mg/ kg :8#@Y G(#:$)$ ( 0.5 t 0.75 mg/
kg 3\ 5 t 10 $ 34 ? 9(#IE :8#FJJ
continuous infusion : 1 t 4 mg/ min
D5W, NSS,
Ringer's and
sodium
bicarbonate
solution
- Direct IV : y# 94AI 9!)#9)#$

20 mg/ ml G9X?#'>!L&'L >
- Continuous IV Infusion : :;# 1 g
)'>E !L&'L >(#IE" %D% E34_
!)# $G(# LY $I$ 1000 ml LDG(#
AI 9!)#9)#$ 1 mg/ ml AI 9
!)#9)#$G9XAI!=$ 8 mg/ ml
- "Y 8JE :$AI 9!)#9)#$ 40, 100
8&' 200 mg/ ml LD:;#"Y 8J
infusion ~_>?#'>!L&'L >X'$:;#
!3X $@$ y# 8 G9XG(#!L&'L >' L3Y
:8#!=( cardiac arrest, seizures
8&'!"4E;4I=?G(#
X'$:8#E K(E IV Infusion :8#}4(

E direct IV X'$ !f&_':8#G(#D(J
E :$!%&'(:$)$ ( 'EX >
I(!MI
- Direct IV :8#:;# Xylocard 100
(100 mg/ 5 ml) :$)$ (
1 mg/ $@Y 8$?I 1 kg }4(!)# !"#$
;# ] K(E:;#!I% 2 $ 34 F%DAI
!=_98E(E !)# !"#$B E:$ 10 $ 34
' L:8#E :$)$ (!(4EI$4@G(#3\
10 - 20 $ 34 F?XG9XAI!=$
300 mg Lignocaine :$
DED!I% 1 ;9.
- IV infusion :8#:;# Xylocard 500
(100 mg/ ml) F%D:;# infusion
pump 8&' microdrip '?
8E(34_F$D$Y A&' 2 - 4 mg/ min
y# 8E(!)# !"#$!MI!=$GH' L3Y :8#
!"4E;4I=?G(#
- " %D% E8%>b"9F%#I?#'>:;#:8#89(B E:$ 12 ;9.

7$ :
- ?IL"'J'? 8E()'>$@Y E 8 8E(!)# !"#$K%8=?
!MI!=$GH' L3Y :8#!"4E;4I=?G(#
- m434_!=(' ;M'A 8I:L8&'?J%#9!8%I AI%()$ (
E %>
- )$ (:;#:$ 34_:8#GI#$4@!Hn$!f4E>AY F$D$Y !3X $@$
D(JE :$ plasma F%D)$ (:;#AIHJ? 9AI 9!89 D"9
)'>F?X%DJ\AA% !$&_'>L ?'J"$'>?X'E 34_F??X >$
- :8#:;#E )$ (?_Y "\(34_" 9 yAIJA\9B ID arrythmias G(#
( therapeutic level 1.5 t 5 mcg/ ml,
toxic level > 5 mcg/ ml)
! :
- D8IX > :8#E AI?=(? 9 ECG 'EX >?X'!$&_'>F%D
?=(? 9 !=( prolonged PR interval 34_9 IX 0.2 I=$ 34
8&'94 QRS complex 9 IX 0.12 I=$ 34 8&'B ID !%I
%>)'> ventricular arrythmias
- ?=(? 9 !=(f=)'>E F%DD(J AST, ALT, BUN
Creatinine F%DD(J electrolytes
overdose : ~9 "J"$ coma ; 8 E:LyN( 94f=?X'
8I:L ; "_$ GI disturbance
- !MJE :$'\m8BN9=34_ 25 OC 8&'?_Y IX
- USFDA Preg Cat B

Lidocain
1% , 50ml
2%, 50ml

/

/

- Local anesthetic, Antiarrthymic agent

D5W, D5S/2,
- Antiarrthymic :
0.45% NaCI, NSS,
!(M : IV ; loading : 1 mg/ kg ? 9(#IE IV
RINGER
continuous infusion y# 8X >$9 IX 15 $ 34
' L:8# bolus !)M934_"'>:$)$ ( 0.5 t 1 mg/ kg
G(#
IV continuous infusion : 20 t 50 g/ kg/ min
y# bN#HpIE shock !Hn$KA?J, cardiac arrest,
mild CHF :8#)$ ( 20 g/ kg/ min
bN#:8<X : IV ; !=_9?#$(#IE)$ ( 1 t 1.5 mg/ kg
8%>L $@$ 5 t 10 $ 34 ' L@Y (#IE 0.5 t 0.75
mg/ kg bolus K(E)$ (E I9G9X!=$ 200 t 300
mg :$D8IX > 1 ;9. 8&' 3 mg/ kg )'>)$ (
E I93@>89(
!

- IM, Direct IV : !)#9)#$1%,

2% G9X?#'>!L&'L >
- Intermittent IV : %D% EE
1 g :$" %D% E34_:;#G(#
'EX >$#'E 250 ml
- IV infusion : %D% EE
2 g :$ D5W 250 ml F%D:;#
infusion pump
- IM, Direct IV : 25 - 50
$ 34 y# :8#!MI!=$GHLD3Y :8#
;G(#
- intermittent IV : 1 t 4 mg/
$ 34
- IV infusion : :;# microdrip
(60 drops/ ml) 8&' infusion
pump
IM, Direct IV, Intermittent IV

Lincomycin
(Lingo)
600 mg/ 2 ml
- Antibiotics ( Lincosamides group)

: IM ; 10 mg/ kg :8#3\ 12 t 24 ;9.
IV ; 10 t 20 mg/ kg/ day FJX>:8#3\ 8 t 12 ;9.
: IM ; 600 mg :8#3\ 12 t 24 ;9.
IV ; 600 t 1000 mg :8#3\ 8 t 12 ;9.
)$ ("N>"\(G9X!=$ 8 g/ day
IM, IV Infusion
D5S, D10S, D5W, - !L&'L > : 1 amp :$

D10 W, RINGER " %D% E34_:;#G(#'EX >$#'E
250 ml (b"9F%#IAI 9
!)#9)#$G9X!=$ 1 g/ 100 ml
)'>" %D% E)
" #/ $
- !9&_'!L&'L >F%#IA>?I 24 ;9.
- 8%>L !H(:;#F%#I94AI 9A>?I 30 I$
- A$G)#34_G(# IV Infusion $ $] DI> !=(
thrombophlebitis
- USFDA Preg Cat B :As LA& cardiac drug

- IV infusion J=8 $ $IX 1 - !L&'L >F%#IAI:;#B E:$ 24 ;9. 34_'\m8BN9=8#'>
;9.
- USFDA Preg Cat B

Meropenem
1g

/

/

- Antibiotic, Carbapenem
NSS, D5W, D10W,

: 20 mg/ kg/ dose :8#3\ 12 ;9.
D5S , RINGER

> 3
(< 50 kg) : 10 t 40 mg/ kg/
dose :8#3\ 8 ;9.

456 > 50 kg : 500 mg - 2 g
3\ 8 ;9. ? 9AI 9\$F>)'>KA
Direct IV,IV Infusion

Methylprednisolone - Corticosteroid system, Anti t inflammatory,
(Sodium succinate) Immunosuppressant
(Solu - Medrol)
- Shock : 30 mg/ kg :8#!I% $ $IX 15 $ 34
1000 mg
- Immunosuppressant : 0.5 - 2 g
(1 gm/ 16 ml)
- Anti t inflammatory : IM ; 10 t 80 mg/ day
IV ; 10 t 40 mg F%D:8#@Y (#IE IV 8&' IM
F%#IF?X ?'J"$'>
3\ 1 - 2 I$
IM, Direct IV, IV Infusiion
NSS, D5S, D5W
!

- Direct IV : %D% E(#IE

- Direct IV : 3 - 5 $ 34
SWFI :8#AI 9!)#9)#$ 50 mg/ (H=9 m 5 - 20 ml)
ml (b>E 500 mg %D% E:$ - Infusion : 15 - 30 $ 34
10 ml, b>E 1000 mg
%D% E:$ 20 ml)
- IV Infusion : %D% E:$
" %D% E34_:;#G(# 50 - 200
ml
- IM Direct IV : %D% E(#IE
?I3Y %D% E34_:8#9 8&'
bacteriostatic water 2 ml
" %D% E34_:)#G(# 50 ml
- IM Direct IV :
'EX >$#'E 1 $ 34
- Infusion:
125 - 500 mg: > 15 - 30$ 34
500 t 1,000 mg: > 30 $ 34
1000 - 1,500 mg: > 60 $ 34
" #/ $
- %D% E:$ SWFI A>?I 2 ;9. 34_'\m8BN9=8#'> F%D 18 ;9.
!9&_':"X:$?N#!EM$
- " %D% E34_:;# Infusion !Hn$ D5W 94AI 9A>?I 1 ;9. 34_
'\m8BN9=8#'> F%D 8 ;9. !9&_':"X:$?N#!EM$
- y# %D% E:$ NSS LD94AI 9A>?I34_'\m8BN9=8#'> 4 ;9
F%D :$?N#!EM$ 24 ;9.
- USFDA Preg Cat B

- 8%>L %D% EF%#I!MJ34_'\m8BN9=8#'>G(#$ $ 48 ;9.
- y# )$ (E < 250 ml LD:8#3 > IM, Direct IV F%D IM
LD:8#A@>%D 5 ml !f&_'%( DA E!A&'>!$&@'!E&_'
- USFDA Preg Cat C

/

/

Metoclopramide
(Plasil)
10 mg/ 2 ml
- Antiemetic, Prokinetic agent

: Gastrointestinal hypomotility : IM,
IV ; 0.1 mg/ kg/ dose :8#G(#"N>"\( 4 A@>?X'
I$ )$ ("N>"\(G9X!=$ 0.5 mg/ kg/ day
Antiemetic : IV ; 1 t 2 mg/ kg/ dose :8#
30 $ 34X'$G(#JE !A94JY J( F%D3\ 2 t 4
;9. :8#G(#"N>"\( 5 A@>?X'I$ )$ ("N>"\(G9X
!=$ 5 - 10 mg/ kg/ day
: Gastrointestinal hypomotility : IV
; 10 mg ' L:8#G(#$ $y~> 10 I$
Antiemetic : IV ; 1 t 2 mg/ kg/ dose :8#
30 $ 34X'$G(#JE !A94JY J( :8#G(#"N>"\( 5
A@>?X'I$
IM, Direct IV, Intermittent IV
- Antibiotic, Antiamoebic, Anaerobic
- Anaerobic infection

: IV ; 30 mg/ kg/ day FJX>:8#3\ 6 ;9.
: IV 500 mg/ dose :8#3\ 6 t 8 ;9.
)$ ("N>"\(G9X!=$ 4 g/ day
IV Infusion
D5W, D5S/2,
D5S, RINGER,
NSS
Metronidazole
500 mg/ 100ml
(0.5%, 100 ml )
Mitomycin - C
5 mg
- Antineoplastic agent, Antibiotic

- Single agent therapy : IV ; 20 mg/ m2
:8#3\ 6 t 8 "H( 8C
- Combination therapy : IV ; 10 mg/ m2
:8#3\ 6 t 8 "H( 8C
Direct IV
!
- IM, Direct IV : G9X?#'>!L&'L >
- Intermittent IV :
)$ ( > 50 mg !L&'L >:$
" %D% E34_:;#G(#'EX >$#'E 50 ml

- IM, Direct IV : 1 - 2 $ 34
!f&_'%( !=( restlessness
L }4(E !MI
- Intermittent IV : 'EX >$#'E
15 $ 34
NSS, D5W,
RINGER
- %D% E:$$@Y %_$, NSS 4.4 ml F%# Slow infusion F?X%D single
I!L&'L >?X':8#AI 9!)#9)#$G9X!=$ 8 dose 'EX >$#'E 1 ;9.
mg/ ml
NSS, D5W,
RINGER
- b>E 5 mg %D% EJ$@Y %_$8&' - Direct IV :

" %D% E34_:;#G(# 10 ml (conc. 0.5
slow 15 - 10 $ 34
t 1 mg/ ml) :8#bX $ Y - tube 8&' 3 - Infusion :
t way stopcock
slow 15 - 30 $ 4
- IV solution X'$F%D8%>:8#E
" #/7$
- 8%>L !L&'L >F%#A>?I 24 ;9.
-:8#X'$:8# chemotherapeutic agent '&_$A~_>)_IK9>
- USFDA Preg Cat B

- 8%>!L&'L >F%#IAI!MJ:8#f#$F">
- 8 F;X:$?N#!EM$?IE ' L?b%~G(#F?Xb%~$4@LD%D% EG(#!'>
!9&_''\X$)~@$F%DLD" 9 y:;#G(# (F$D$Y :8#!MJ34_ 15 - 30 '>a
G9XAI!MJ:$?N#!EM$) :;#B E:$ 24 ;9.
- !H(F%#I:;#G(# 30 I$
- USFDA Preg Cat B (' L8# 9:;#:$G?9 aF)
- " %D% E34_G(#A>?I 14 I$:$?N#!EM$ 7 I$34_'\m8BN9=8#'>
Hl'>$F"> (conc. 0.5 t 1 mg/ ml)
- 8 " %D% E34_G(#!L&'L >?X':$ NSS, Sodium lactate
(conc. 20 t 40 g/ ml)
A>?IG(# 12 ;9. F%D 24 ;9. ? 9%Y (J34_'\m8BN9=8#'>
- USFDA Preg Cat X

/

/

!

Magnesium
sulphate (Epsom
salt)
10% , 10 ml
50% , 2 ml
- :;# B ID hypomagnesemia, Hl'>$

;:$ severe pereclampsia 8&'
eclampsia, Pediatric acute nephritis,
torsade de point, cardiac arrest
- Hypomagnesemia
Children :
IM, IV : 25 t 50 mg/ kg/ dose (0.2 t 04
mEq/ kg/ dose) 3\ 4 - 6 ;9. 3 t 4 dose
)$ ("N>"\(G9X!=$ 2000 mg (16 mEq)
maintenance IV 30 t 60 mg/ kg/ day (0.25
t 0.5 mEq/ kg/ day)
Adult : IM, IV : 1 g 3\ 6 ;9. :8# 4 dose y#
\$F>' L:8# 8 t 12 g/ day
- Seizures :Children: IV : 20 t 100
mg/ kg/ dose 3\ 4 - 6 ;9. m434_\$F>
' L:8#G(#"N>y~> 200 mg/ kg/ dose
- Eclampsia F%D pre-eclampsia :
Adult : IM ; 1 - 4 g 3\ 4 ;9., IV ; !=_9?#$:8#
4 g L $@$!H%4_E$!Hn$:8# IM 8&' IV Infusion
1 - 4 g/ hr )$ ("N>"\(G9X!=$ 30 t 40 g/ day
F%D'? !MI:$ :8#G9X!=$ 1 t 2 g/ hr
- Life threatening arrhythmia : IV ; 1 t 2 g
(8 t 16 mEq) b"9(#IE D5W 100 ml :8#$ $
5 t 60 $ 34 ? 9(#IE IV infusion 0.5 t 1 g/
hr 8&':8# 3 t 20 mg/ min $ $ 5 t 48 ;9.
IV, IM, IV push, IV Infusion
NSS, D5W,
RINGER
- Direct IV : !)#9)#$ 10%

G9X?#'>!L&'L >
- Intermittent IV : $;
- !L&'L > 4 g :$" %D% E34_:;#G(#
250 ml
- !L&'L > 5 g :$" %D% E34_:;#G(#
1000 ml
- IM, IV push AI94 !L&'L >E F%D

:;#E 34_94AI 9!)#9)#$G9X!=$ 20% (200
mg/ ml) '? !MI:$ :8#E G9X!=$ 1.5
ml/ min 8&' 150 mg/ min
- Life - threatening arrhythmia:
IV push : 1 - 2 g (8 - 16 mEq)
!L&'L >:$ D5W 100 ml :8#E $ $
5 - 60 $ 34 F%D? 9(#IE :8#FJJ
IV Infusion '? !MI"N>"\(:$ 8E(E
0.5 -1 g/ hr
- IV Infusion : :;#!I% :$ 8E(E
$ $IX 2 - 4 ;9. (G9X!=$ 125 mg/
kg/ hr 8&' 1 mEq/ kg/ hr) '? !MI
"N>"\(:$ 8E(E !)# 8%'(!%&'( 1 - 2
g/ hr
- m4}\!}=$ (;) ' LLD:8# 4 g/ hr
** Maximum rate of infusion: 2 gm/
;9. Hl'>$ hypotension
** )$ (E "N>"\(G9XAI!=$ 30 - 40 g/
day '? :8#E infusion "N>"\(
G9X!=$ 1 - 2 g/ hr
( IV Infusion: !L&'L >E :8#94AI 9

!)#9)#$"N>"\( 100 mg/ ml)
" #/ 7$
- 8# 9b"9I9J fat emulsion, calcium
gluceptate, clindamycin, tolbutamine,
hydrocortisone (same syringe), nafcillin,
polymixin B, procaine hydrochloride,
tetracyclines, thiopental
- monitor : BP, serum Mg (Hl'>$ overdose),
diarrhea, arrthymias, hypotension, CNS
7$ :
- 8# 9:;#JbN#HpIEKAG?34_94 Clcr < 25 ml/ min
- :8#E (#IE'? !MI"N>?#'>DI> !=(
Hypotension
!: Arrhythmias, hypotension,
diarrhea, respiratory and CNS depression
D8IX > :8#E FJJ Rapid IV, ?=(? 9D(J
serum magnesium !f&_'Hl'>$ overdose
E$A : room temperature (!MJ34_
'\m8BN9=8#'>'\m8BN9=G9X!=$ 40 OC)
- 8# 9F;X!EM$!$&_'>L E LD??D'$
- USFDA Preg Cat B

/

/

!

" #/ 7$
Midazolam
injection
1 mg/ ml
- :;#!Hn$E ">JD>JHD" 3!f&_'!?4E9bN#HpIEX'$ bX ?(8&'

?ILI=$=L}E
W
:
- "Y 8J :"X!A&_'>;XIE8 E:L ; IV Infusion 0.15 - 1 mcg/ kg/ min
Y
5
:
- "Y 8J :"X!A&_'>;XIE8 E:L ; IV Infusion : 0.15 - 0.5 mcg/ kg/
min
> 2

:
- X'$ bX ?( : IM ; 0.08 mg/ kg X'$ bX ?( 30 - 60 $ 34 , IV ;
0.035 mg/ kg/ dose :8#@Y G(#F?X)$ (E I9G9X!=$ 0.1 - 0.2 mg/ kg
- "Y 8J :"X!A&_'>;XIE8 E:L : IV : loading dose 0.05 - 0.2 mg/
kg ? 9(#IE IV Infusion 1 - 2 mcg/ kg/ min HJL$G(#b% ''3=
34_?#'> )$ (H?=34_:;#A&' 0.4 - 6 mcg/ kg/ min
- Conscious sedation: IV : 0.05 mg/ kg X'$ 3Y 8?y 3 $ 34

- X'$ bX ?( : IM ; 0.07 - 0.08 mg/ kg X'$ bX ?( 30 - 60
$ 34 (' E\ < 60 H| :;# 5 mg, > 60 H| :;# 2 t 3 mg), IV ; 0.02 t 0.04
mg/ kg y# LY !Hn$:8#@Y G(#3\ 5 $ 34
- Conscious sedation: IV )$ (!=_9?#$ 0.5 - 2 mg slow IV $ $'EX >
$#'E 2 $ 34 HJ)$ (E ? 9?#'> ' L:8#@Y G(#3\ 2-3 $ 34
)$ (E I9G9X!=$ 2.5 - 5 mg
- Anesthesia : IV ; Unpremedicate pt : 0.3 t 0.35 mg/ kg
Premedicate pt : 0.15 t 0.35 mg/ kg
Maintenance : 0.05 t 0.3 mg/ kg y# ?#'> 8&':8# continuous IV
infusion 0.25 t 1.5 g/ kg/ min
IM, IV, IV Infusion
0.9% NSS,
D5W,
!?4E9$@Y E "Y 8J:8#3 >

8%'(!%&'( : " %D% E
Midazolam L )I(E " 9 y
!L&'L >G(#K(E:;#" %D% E :$
'? "XI$ Midazolam 15 mg
:$" %D% E"Y 8J:8#3 >
8%'(!%&'( 100 - 1000 ml
AI 9!)#9)#$"N>"\()'>
" %D% EG9X!=$ 0.5 mg/ ml
- Deep IM : }4(!)# %# 9!$&@'9(

:8<X
- Slow IV : K(E:8#E $ $IX
2 - 5 $ 34
- Continuous IV Infusion
- " %D% E34_b"9 D5W F%D NSS F%#I

LD94AI 9A>?I 24 ;9. !9&_'!MJGI#34_
'\m8BN9=8#'>
- " %D% E34_b"9 Ringer F%#ILD94AI 9
A>?I 4 ;9. !9&_'!MJGI#34_'\m8BN9=8#'>
- G9XLY !Hn$?#'>Hl'>$F">
!: Respiratory and
cardiovascular status, blood pressure
LD?=(? 9:$m434_:8# IV
Z [ : Midazolam !Hn$
short - acting benzodiazepines ~_>
bN#HpIE"XI$:8<XLD?&_$B E:$ 2 ;9. F?X
:$J > E' L?&_$:$ 6 ;9.
5% dextrose,
RINGER
- USFDA Preg Cat D

/

/
Morphine sulphate
10 mg/ ml, 1 ml
- Analgesic, Narcotic
- Acute pain (moderate - severe)

> 6 (456 < 50 kg) :
IM ; 0.1 mg/ kg :8#@Y 3\ 3 t 4 ;9. y# LY !Hn$
IV ; 0.05 t 0.1 mg/ kg :8#@Y 3\ 3 t 4 ;9. y# LY !Hn$
IV infusion range : 10 t 30 g/ kg/ hr
- ' HI(8%>bX ?( : 0.01 t 0.04 mg/ kg/ hr
- :;#">JD>JF%DJ!3 ' HI(D8IX > 3Y
8?y : IV : 0.05 t 0.1 mg/ kg 5 $ 34X'$ 3Y
8?y
- :;#">JD>JF%DJ!3 ' HI(D8IX >3Y 8?y

J= 12 : IV : 3 t 4 mg @Y G(#3\ 5 $ 34y#
LY !Hn$
- Acute pain (moderate - severe)
: IM, IV, SC : 2.5 - 5 mg/ dose 3\ 3 - 4 ;9.
AX'E] !f=_9)$ ()~@$34%D 1 t 4 L$G(# ?'J"$'>34_
?#'>
IV, SC, Continuous infusion : 0.8 t 10 mg/ hr )$ (
E H?=G9XAI!=$ 80 mg/ hr
Epidural : !=_9?#$(#IE 1 t 6 mg :8# infusion ?X'(#IE
'? !MI 0.1 t 1 mg/ hr )$ (E "N>"\(G9X!=$ 10 mg :$
24 ;9.
IM, IV, SC, Continuous infusion

Ringer, D5W,
D10W, NSS,
Dextran, DRinger, D-S,
0.45 % NaCI
!

" #/ $
- IV push: !L&'L >E (#IE

Sterile water for Injection
8&' D5W 'EX >$#'E 5 ml
AI 9!)#9)#$34_:;#
0.5 t 5 mg/ ml
- IV Infusion: !L&'L >E (#IE
D5W :8#94AI 9!)#9)#$
0.1 t 1 mg/ ml
8%>L !L&'L >F%#IAI:;#
3$34 !!
\8 !

- }4(!)# %# 9 (IM) F%D}4(

!)# :?#b=I8$> (SC) $ $ 3 t
5 $ 34
- }4(!)# !E&_'8\#9"9'>F%DG)
"$8%>;@$$' (Epidural)
:;# ;$=(G9X94 preservative
- }4(!)# G)"$8%>
(Intrathecal)
:;#;$=(34_G9X94 Preservative
- IV Infusion :8#:$'? !MI
1 t 10 mg/ hr K(E:;#
Infusion pump
- IV push K(E$Y GH!L&'L >
:$ Sterile water for
Injection 4 - 5 ml }4('EX >
;# ] $ $ 4 - 5 $ 34
- 8 E "% E?ILD!=("4!8%&'>8&'$@Y ? %F%D

8# 9:;#!9&_'94 ??D'$!=()~@$8&'94"4!8%&'>!)#9)~@$
- !MJ:8#f#$F">
- 8%>!L&'L >F%#IAI:;#3$34
- :8#'EX >I(!MI' L3Y :8#( 8 E:L, AI 9($
K%8=??_Y G(# F%DA$G)#' LLDy~>? EG(#
- Monitor : pain relief, respiratory and mental
status, BP
overdose : ( 8 E:L 9X $? )E E AI 9
($K%8=??_Y 8I:L!?#$;# 8E\(8 E:L pulmonary
edema
UV:
IM; peak 30 - 60 $ 34
DED!I% 4 - 5 ;9.
IV ; peak 20 $ 34 DED!I%
4 - 5 ;9.
! M :
E 94 2 NHFJJ A&'
1. 94 Preservative : !
E K(E
- }4(!)# !E&_'8\#9"9'>F%DG)"$8%>;@$$' (Epidural)
- }4(!)# G)"$8%> (Intrathecal)
2. G994 Preservative (preservative-free solution)
" 9 y:8#G(#K(E
- }4(!)# !E&_'8\#9"9'>F%DG)"$8%>;@$$' (Epidural)
- }4(!)# G)"$8%> (Intrathecal)
- USFDA Preg Cat C : D (y# :;#!Hn$DED!I% $ $

8&':;#:$)$ (34_"N>)

/

/
Nitroglycerin, NTG - :;#:$B ID Congestive heart failure

(Glyecryl trinitrate) 34!_ =(XI9J myocardial infarction,
50 mg/ 10 ml
pulmonary hypertension,
hypertensive emergencies

: Continuos infusion ; )$ (E
!=_9?#$ 0.25 t 0.5 g/ kg/ min !f=_9
)$ (A@>%D 1 g/ kg/ min 3\ 20 F%D
60 $ 34 ? 9?#'>
)$ (H?=!3X J 1 t 3 g/ kg/ min
)$ (E "N>"\(A&' 5 g/ kg/ min
:
)$ (E !=_9?#$ 5 g/ min !f=_9)$ (A@>
%D 5 g/ min 3\ 3 t 5 $ 34 L$G(#
)$ ( 20 g/ min y# bN#HpIEE>G9X
?'J"$'> :8#!f=_9)$ (A@>%D 10 g/
min 3\ 3 t 5 $ 34 K(E)$ (E "N>"\(
G9X!=$ 200 mcg/ min
Continuous IV Infusion

!
NSS, D5W
- IV Infusion %D% E?IE 50 mg :$

" %D% E34_!89 D"9A&' NSS, D5W 250
8&' 500 ml 8&' %D% E?IE 100 mg :$
" %D% E 250 ml !f&_':8#G(#" D% E
AI 9!)#9)#$D8IX > 50 t 200 g/ ml
- AI 9!)#9)#$"N>"\(G9X!=$ 400 g/ ml

" #/7$
- 8%>!L&'L >:$ glass container F%#IA>?I 48 ;9.
34_'\m8BN9=8#'> F%D 7 I$ !9&_'!MJ:$?N#!EM$
7$ :
- Nitroglycerin !)# $G9XG(#Jy\>f% "?=;$=($=_9 PVC !$&_'>L
PVC LD(N(~9?IE GI# L~>AI!?4E9E :$)I(F#I F%D:;# infusion
pack 34_3Y 9 L polyethylene (Non-PVC plastic)
- :8#:;#E 'EX >D9(DI>:$bN#HpIE severe hepatic 8&' renal
disease
- ' L!=(' HI(a4DF%DA%&_$G"#D8IX >:8#E
- ' L3Y :8#AI 9($%(?_Y %>'EX >9 8I:L!?#$!MIb=(H?= !8>&_'
G8%9 D"JD"X E %# 9!$&@'D?\ '~('(:$;X'>' HI(
B E:$;X'>3#'> ' LfJ !=( paradoxical 8I:L!?#$;# b=(H?=
- :8#E AI:;# infusion pump
overdose : AI 9($K%8=??_Y 8$# F(> 89("?= HI(8I 8I:L!?#$
!MI methemoglobin AI 9($:$"9'>!f=_9)~@$ "J"$ !I4E$a4D
:L"_$ A%&_$G"# ' !L4E$ 8'J heartblock 8I:L!?#$;# %> coma ;
!"4E;4I=?
- Tolerance ' L!=()~@$ y# :8#9 IX 12 t 24 ;9.
- AIJL\:$B ;$DF#ILDyN(N(JL plastic PVC
! : Blood pressure, heart rate
- !MJE 34_'\m8BN9=G9X!=$ 25 OC !MJ:8#f#$F">
- USFDA Preg Cat C

Nadroparin cal.
(Fraxiparin)
3800 iu/ 0.4 ml

/

/
- Anticoagulant
- Dose variable

!

NSS, D5W
- Direct IV : G9X?#'>!L&'L >:$

E opioid overdose 8&'
!L&'L >(#IE$@Y %_$, NSS 10 ml
:$ EDJJ8 E:LyN(
opioid
" %D% E34_:;#G(#:8#G(#AI 9
!)#9)#$ 4 g/ ml (1 amp/ 100
ml solution)
G9X?#'>!L&'L >' L:8#bX $
Y - tube 8&' 3 - way
stopcock
- IV push : :8#$ $IX 30 I=$ 34

- IV : Loading 0.4 mg ? 9(#IE
infusion 0.4 mg/ hr (bN#:8<X) 8&'
0.024 t 0.16 mg/ kg/ hr (!(M)
- IV infusion : 3.7 g/ kg/ hr
SC
Naloxone
0.4 mg/ ml, 1 ml
Neostigmine
(Prostigmine)
2.5 mg/ ml, 1 ml
- Antidote morphine Opiate intoxication

-
< 5 456 < 20 kg :
IV ; 0.1 mg/ kg :8#@Y 3\ 2 t 3 $ 34 y# LY !Hn$
8&':8#3\ 20 t 60 $ 34
-
> 5 456 > 20 kg :
IV ; 0.2 mg/ kg :8#@Y 3\ 2 t 3 $ 34 y# LY !Hn$
- : IV ; 0.4 t 2 mg :8#@Y 3\ 2 t 3 $ 34
y# LY !Hn$ K(E)$ (E "N>"\(G9X!=$ 10 mg
Sc, IM, Direct IV, IV Infusion
- Acetylcholinesterase inhibitor
- Myasthenia gravis diagnosis : IM ;

: 0.04 mg/ kg single dose
: 0.02 mg/ kg single dose
- Myasthenia gravis treatment : IM, IV, SC ;

: 0.01 t 0.04 mg/ kg :8#3\ 2 t 4 ;9.
: 0.5 t 2.5 mg/ kg :8#3\ 1 t 3 ;9.
K(E)$ ("N>"\(G9X!=$ 10 g/ 24 hr
IM, Direct IV
0.5 mg/ $ 34
" #/7$
- }4(J=!Im8$# 3#'>K(EF3>!)M9%>?>GH34_;@$
subcutaneous A%# E }4( Insulin
- 8# 9F;X!EM$
- USFDA Preg Cat B
- :8#!)# IV LD!Hn$ route 34_$=E99 34_"\(
- 8%>L %D% EF%#I" %D% E94AI 9A>?I 24 ;9.
- USFDA Preg Cat C

- 8 :8# IV LY !Hn$?#'>'ENXB E:?# (NF%)'>Ff3EC
- !MJE G(# 24 ;9.
- AI8E\(:;#E %\X9 anti t cholinesterase X'$:8#E 'EX >
$#'E 8 ;9.
! : pulse, respiratory rate F%D blood pressure
- USFDA Preg Cat C ; D

Nitroprusside
Sodium
50 mg/ ml
Oxytocin
(Syntocinon)
10 u/ ml

/

/

- Antihypertensive, Vasodilator
- Pulmonary hypertension

: IV infusion; !=_9(#IE 1 g/ kg/ min
!f=_9G(#A@>%D 1 g/ kg/ min 3\ 20 t 60
$ 34 ? 9AI 9LY !Hn$
)$ (E H?= : 3 g/ kg/ min
)$ (E "N>"\( : 5 g/ kg/ min
: IV infusion ; !=_9(#IE 0.3 t 0.5
g/ kg/ min !f=_9G(#A@>%D 0.5 g/ kg/
min
)$ (E H?= : 3 g/ kg/ min
)$ (E "N>"\( : 10 g/ kg/ min
IV Infusion
- Oxytocic agent
- Induction of labor
: IV infusion ; 0.5 t 1 milliunits/
min !f=_9)$ (A@>%D 1 t 2 milliunits/ min
L$D3_>G(# ?'J"$'>34_?#'>
:8#:$)$ ( 6 milliunits/ min LD3Y :8#G(#
?'J"$'>:%#!A4E>9; ?=
- Postpartum bleeding :
IM ; )$ (E I9 10 units :8#8%>A%'(
IV ; 10 t 40 units b"9J" $@Y 1000
ml :8#:$'? 34_" 9 yAIJA\9uterine
atony G(#
IV Infusion
D5W
D5W, D10W,
0.45 NaCI,
Dextrose, NSS
!

- %D% EE 50 mg :$$@Y %_$ 2 - 3 - !9&_':8#E !Hn$DED!I% $ $G9X

ml F%#I!L&'L >?X':$ D5W H=9 m AI:8#!MIIX 2 g/ kg/ min
250 - 1000 ml
!f DLD3Y :8#!=( "D"9)'>
cyanide 9 !=$L$X > E3$
G9XG(#
- $@Y E 34_%D% E:89XLD94_"4
$@Y ? %'X'$8 !H%4_E$"4 F"(>IX
E "% E?I
- !L&'L >E 1 ml (10 unit) %>:$

- AI:;# infusion pump
" %D% E34_:;#G(# 1000 ml :8#94
oxytocin 10 milliunits/ ml FIX>:8#
!)# $
" #/7$
- 8%>L %D% EF%D!L&'L >F%#IAI!MJ:8#f#$F">F%D:;#
B E:$ 24 ;9.
- USFDA Preg Cat C

- !MJ34_'\m8BN9= 2 - 8 OC 8# 9F;XF)M>'ENXG(# 30 I$
! : BP ' L!=( hypotension, cardiac
arrththemia uterine rupture, fluid intake F%D output, fetal
- USFDA Preg Cat X

/

/

Omeprazole
(Losec, Miracid)
40 mg
- Proton pump inhibitor

- )$ ( :8#E 40 mg I$%DA@>
!f&_'AIJA\9 pH
- y# severe !=_9 80 mg bolus
8%>L $@$ 40 mg 3\ 8 - 12 ;9
L$AJ 72 ;9. L~>:8#E }4( 8&'E :$
NHFJJJHD3 $)$ ( 40 mg I$%DA@>
IV
- Analgesic
- )$ ( :8#E 300 mg 3\ 6 ;9.
IM
- Antibiotics, Penicillins
bN#:8<X : IM ;
- Group A streptococcal upper
respiratory infection : 1.2 mu single
dose
- Rheumatic fever prophylaxis : 1.2 mu
:8#3\ 3 t 4 "H( 8C 8&'FJX>:8#!(&'$%D 2
A@> A@>%D 0.6 mu
- Early syphilis : 2.4 mu single dose )# >
%D!)M9
- Syphilis 34_!Hn$9 $ $IX 1 H| : 2.4 mu
}4()# >%D 1 !)M9 ?=(?X'$$ $ 3 "H( 8C
Note: G9XG(#DJ\:8#:;#:$ Neurosyphilis F?X
' L:8# "H( 8C%DA@>?=(?X'$ 3 "H( 8C
IM
Paracetamol
300 mg/ 2 ml
Penicllin G
Benzathine
1,200,000 mu
!

- %D% E(#IE?I3Y %D% E34_:8#9
" #/7$
- 8%>L %D% EF%#I!MJG(#$ $ 4 ;9.
- :8#;# ] !f D' LLD!=( Plebitis G(#
40 mg :$ 3 $ 34 8 :8#:$'?
34_!MI!=$GH' LHI(8&'!=(8%'(
!%&'('!"JG(#
- %D% Eb>E 1.2 mu :$$@Y %_$

3.6 ml
- USFDA Preg Cat C

- y 9HDI?= Ff#E )'>bN#HpIEX'$}4(
- USFDA Preg Cat B

- 8%>%D% EF%#IAI:;#B E:$ 24 ;9.
- USFDA Preg Cat B

/

/
Penicillin G
- Antibiotics, Penicillins
sodium
- ?=(!;&@'3_IGH : IM, IV ; Infant :

(Benzyl Penicillin
M (day) Z
(unit/ kg/
8[ $ (g)
,PenicillinG,PGS)
day)
100,000
1,000,000 U F%D > 7 > 2000
>
7
<
2000
75,000
5,000,000 U
<7
<7
> 2000
< 2000
50,000
50,000

NSS, D5W

(hr)
6
8
8
12
Infant
: 100,000 t 250,000
unit/ kg/ day FJX>:8#3\ 4 ;9. y# ?=(!;&@'
\$F> :8#G(#y~> 400,000 unit/ kg/ day
FJX>:8#3\ 4 ;9. K(E)$ ("N>"\(G9X!=$ 24
mu/ day
: 2 t 24 mu/ day FJX>:8#3\ 4 ;9.
)~@$J ?'J"$'>?X'E F%DAI 9
\$F>)'> ?=(!;&@'
- Congenital syphilis
Newborn : 50,000 u/ kg/ day FJX>:8#3\
8 t 12 ;9. $ $ 10 t 14 I$
Infant : 50,000 u/ kg/ day :8#3\ 4 t 6
;9. $ $ 10 t 14 I$
- Gonococcal infection : 100,000 u/ kg/
day FJX>:8#!3X $ 2 A@> (y# !(M' E\$#'E
IX 1 "H( 8C FJX>:8#A@>%D!3X ] $ 4
A@>?X'I$)
IM, IV Infusion
!
- IM : !)#9)#$G9X!=$
100,000 u/ ml %D% E 1 mu
F%D 5 mu :$$@Y %_$8&'
" %D% E34_:;#G(# 50 ml
- Infusion : !L&'L >E :$
" %D% E34_:;#G(#
1,000 ml - 2,000 ml

- Intermittent IV: 1 t 2 ;9. :8#
'EX >I(!MI8&'9 !=$GH' L3Y :8#
!=(AI 9G9X"9(\%)'> electrolyte
8&';G(#
- IV Infusion : ?%'( 24 ;9.
" #/7$
- 8%>%D% EF%#IAI:;#B E:$ 7 I$34_'\m8BN9=?N#!EM$
- 8%>!L&'L >F%#IAI:)#B E:$ 24 ;9. 34_'\m8BN9=8#'>
- !H%4_E$34_}4(3\ 48 ;9. !f&_'Hl'>$ phlebitis
- USFDA Preg Cat B

Phenobarbital
(Gardenal)
200 mg/ ml

/

/

- Anticonvulsant
Loading dose IV :
Infant & children : 10 t 20 mg/ kg, single
dose 8&'FJX>:8# :$bN#HpIEJ > E' L:8#:$
)$ ( 5 mg/ kg/ dose 3\ 15 t 30 $ 34 L$
AIJA\9' ;G(# K(E)$ (I9G9X!=$ 40
mg/ kg
Adult : 300 t 800 mg 8%>L $@$:8# 120 t
240 mg/ dose 3\ 20 $ 34 L$AIJA\9'
G(# K(E)$ (E I9G9X!=$ 2000 mg
Maintenance IV :
Infant : 5 t 8 mg/ kg FJX>:8# 1 t 2 A@>?X'I$
Children 1 5 : 6 t 8 mg/ kg/ day FJX>
:8#I$%D 1 t 2 A@>
Children 5 12 : 4 t 6 mg/ kg/ day FJX>
:8#I$%D 1 t 2 A@>
Children >12 & Adult : 1 t 3 mg/ kg/
day FJX>:8#I$%D 2 t 3 A@> 8&' 50 t 100
mg :8# 2 t 3 A@>?X'I$
D5W, D10W
,0.45 %NaCI,
NSS
SC, IM, Direct IV
!
- Direct IV : %D% E(#IE
$@Y %_$'EX >$#'E 3 ml

- G9XAI:8#E !MIIX 50 mg/ min
- :8#'EX >I(!MI' L(DJJ
3 >!(=$8 E:LG(# AI8%4!%4_E>
}4(!)# 8%'(!%&'(F(>
" #/7$
- " %D% E34_94?D'$G9XAI:;#
- 8%>L !H(:;#!=$ 30 $ 34 :8#3=@>GH
! : phenobarb serum concentration, mental
status, CBC, LFTs, seizure activity
- USFDA Preg Cat D

Phenytoin
(Dilantin)
250 mg/ 5ml

/

/

- Anticonvulsant
- )$ ( :8#E
Loading dose IV :
Infant & children : 15 t 20 mg/ kg single
dose 8&'FJX>:8#
Adult : 10 t 15 mg/ kg
Maintenance dose :
Infant & children : 5 mg/ kg/ day FJX>:8# 2
A@> F%#I? 9(#IE
)$ (E H?= :
6 !(&'$ t 3 H| : 8 t 10 mg/ kg/ day
4 H| t 6 H| : 7.5 t 9 mg/ kg/ day
7 H| t 9 H| : 7 t 8 mg/ kg/ day
10 H| t 16 H| : 6 t 7 mg/ kg/ day
Adult : 300 mg/ day 8&':8# 5 t 6 mg/ day
FJX>:8#I$%D 3 A@> y# !Hn$ extended
release :8#I$%D 1 t 2 A@>
NSS
!
- Direct IV : G9X?#'>!L&'L >
- Infusion : !L&'L >:$ NSS
G9X!=$ 50 ml LD(434_"\(8&'
!L&'L >K(E total volume
G9X!=$ 100 ml
D5W

" #/7$
- Direct IV : G9X!=$ 50 mg/ $ 34

y# :8#!MI!=$GHLD3Y :8#!=(
Severe hypotension
- Intermittent IV : 4 ;9. :$'? 34_G9X
!=$ 50 mg/ min AI:8# NSS flush
:$!)M934_:8#!f&_'Hl'>$ DA E!A&'>
!"#$!%&'(
- y# :8#:$'? !MI9 IX 20 mg
/min LD!f=_9K' "!"4_E>?X' Ff#
- !9&_'!L&'L >F%#IAI:;#3$34G9XAIF;X?N#!EM$ !f DLD3Y :8#E

??D'$G(#
- 8%>L b"9F%#I94AI 9A>?I 4 ;9.
- :8# Intermittent IV m4 )$ ( :;#E > 1 g
- y# $@Y E 94"4!8%&'>'X'$, :"" 9 y:;#G(#
- 8%4!%4_E> }4( IM !f DLDHI(9
! : BP, EKG Vitalsign (IV used), plasma
phynytoin level, CBC, LFT
- USFDA Preg Cat D

Potassium
chioride
Injection

/

/
- Electrolyte supplement
40 mEq/ m2/ day
- B ID hypokalemia
- Normal daily requirement : IV ;

Pre mature infant : 2 t 6 mEq/ kg/ 24 hr
Term infant 0 24 hr : 0 t 2 mEq/ kg/ 24 hr
Term infant 0 24 hr : 0 t 2 mEq/ kg/ 24 hr
Infant > 24 hr : 1 t 2 mEq/ kg/ 24 hr
Children : 2 t 3 mEq/ kg/ 24 hr
Adult : 40 t 80 mEq/ kg/ 24 hr
- Treatment of hypokalemia
Children : IV ; 1 t 2 mEq/ kg :8#$ $IX 1 t 2 hr
IV infusion ; )$ (G9X!=$ 1 mEq/ kg/ hr 8&' 40
mEq/ hr y# :8#!=$IX 0.5 mEq/ kg/ hr bN#HpIEAI
G(#J ?=(? 9 EKG ?%'(!I%
)$ ("N>"\(G9X!=$ 3 mEq/ kg/ day 8&' 40 mEq/
m2/ day
Adult : IV intermittent infusion : 5 t 10 mEq/ hr
)$ ("N>"\(G9X!=$ 400 mEq/ day
intermittent IV, IV infusion

D5S, D5S/2,
D5W, D10W,
RINGER
!

" #/7$
- X'$:8#E LY !Hn$?#'>
!L&'L > K(EAI 9!)M9
)#$G9XAI9 IX 40
mEq/ L !I#$:$B ID
}\!}=$' L:;#AI 9
!)#9)#$"N>"\(!3X J 80
mEq/ L " %D% E34_
!L&'L >F%#IAI:;#
B E:$ 24 ;9.
(!L&'L >:$" %D% E
34_:;#G(# 100 - 1,000
ml)
- IV Intermittent infusion :$!(M :

'? :8#E G9X!=$ 1 mEq/ kg/ hr
8&' 40 mEq/ hr y# '? !MI9 IX
0.5 mEq/ kg/ hr Ff3ECAI(NF%A$G)#
'EX >:%#;=( F%D?=(? 9AX EKG 'EX >
?X'!$&_'>
- IV Intermittent infusion :$bN#:8<X :
'? :8#E G9X!=$ 5 - 10 mEq/ hr
y# '? !MI9 IX 5 mEq/ hr AI94
?=(? 9DJJ8I:L'EX >?X'!$&_'>
F%DG9XAI!=$ 40 mEq/ hr )$ (E
"N>"\( 400 mEq/ day
- !9&_'!L&'L >F%#IA>?I 24 ;9. .

- KCl 80 mEq/ L :$ D5W 34_94 silica + aluminium LD
??D'$
7$ :
- G9XAI:8#E 34_G9XG(#!L&'L >
- Potassium chloride inj AI:8#:$bN#HpIE34_94 urine flow
!f4E>f'!3X $@$
- :$bN#HpIE34_94B ID) ($@Y AI:8#" %D% E34_G9X94KHF?
"!4E9LY $I$ 1 %=?X'$:8#KHF?"!4E9
- b"9KHF?"!4E9A%'G(C %>:$y\>" %D% E34_F)I$
GI#' L3Y :8#!=(B ID hyperkalemia G(#!$&_'>L b"9
" %D% EB E:$y\>G9X(4f'(>$@$!9&_'b"9 KCL %>:$y\>
" %D% EAIFIX>y\>GH9 !f&_'Hl'>$ !=(AI 9G9X
"9_Y !"9')'>" %D% EE
- G9XAI:8# KCL 8%> bX ?(L$D3_>bN#HpIE" 9 y
H"" ID''G(#
!: Serum potassium, glucose, chloride, pH,
urine output, cardiac monitor (if intermittent infusion or
potassium infusion rate > 0.25 mEq/ kg/ hr)
overdose : %# 9!$&@''X'$F>, paralysis, EKG b=(H?= (T
wave "N> P wave J prolonged QRS complex),
ventricular arrythmias
E$A : '\m8BN9=D8IX > 15 t 30 C
- USFDA Preg Cat A

Propofol
injection
10 mg/ ml

/

/

!
- :;#;$Y F%D B ID"%J

J= 3 :
- ;$Y "%J : 2.5 t 3.5 mg/ kg :8#:$!I%
20 t 30 I=$ 34
- "B ID "%J : IV Infusion
125 t 300 g/ kg/ min (7.5 t 18 mg/ kg/ hr) 8%>L
$@$ 30 $ 34L~>%()$ (E %>
:
- ;$Y "%J
<== 55 : :8#)$ (E !3X J
2 t 2.5 mg/ kg K(E3_IGH:8#)$ ( 40 mg Bolus 3\ 10
I=$ 34 L$G(# ?'J"$'>34_?#'> F%D)~@$J
!H%4_E$FH%>)'> vital sign 8%>L $@$L~>:8#E ?X':$
)$ ( 150 t 200 g/ kg/ min $ $ 10 t 15 $ 34 %(
)$ (E %> 30 t 50 % :$;XI> 30 $ 34F)'>
maintenance K(E)$ (H?=A&' 100 t 200 g/ kg/ min
(6 t 12 mg/ kg/ hr)
O D JHL= hypovolumic : 1 t 1.5 mg/
kg 8%>L $@$L~>:8#E ?X':$)$ ( 0.05 t 0.1 mg/ kg/
min (3 t 6 mg/ kg/ hr)
D5W
G9XLY !Hn$?#'>!L&'L > F?Xy#

?#'> !L&'L > :8#!L&'L >:$
D5W :8#G(#AI 9!)#9)#$ 2 mg/ ml
(E 1 ml )'>b"9J" %D% E
4 ml)
IV Infusion

" #/7$
- 8%>!L&'L >F%#IAI:;#3$34 b"9F%#I" %D% ELD94AI 9A>?I34_
'\m8BN9=8#'> 8 ;9.
7$ :
- AX 3 >!B";L%$a "?CG9X!H%4_E$FH%>:$bN#HpIEKA?JF%DG?
- :8#E :$'? 34_!MI!=$GHLD94b%?X'DJJ8I:LF%D8 E:L
K(E!}f D:$bN#"N>' E\
- E ' L3Y :8#H"" ID!H%4_E$!Hn$"4!)4EI
- 8# 9:;#FbX$'>!%MIX 5 G9A'$
- !: !=(B IDAI 9($K%8=??_Y F%D8I:L!?#$;# %>
B ID 8E\(8 E:L' L!=(D8IX > ;$Y "%JF%D' L
!=($ $y~> 1 $ 34 AI;XIE8 E:L
- E: Hl'>$F"> '\m8BN9=D8IX > 2 t 22 C @!
Z$8 !

- USFDA Preg Cat B

Pethidine inj
50 mg/ ml
(Mepiridine)

/

/

SWFI, D5W, NSS,

- Analgesic, Narcotic
Dextrose - saline

: IM, IV, SC: 1 t 1.5 mg/ kg
/dose 3\ 3 t 4 ;9. K(E)$ ("N>"\(
G9X!=$ 100 mg/ dose
: IM, SC: 50 t 150 mg/ dose
3\ 2 t 4 ;9. ? 9AI 9LY !Hn$
(bN#HpIEA%'(:;#)$ ( 50 t 100 mg/
dose)
Slow IV ; !=_934_ 5 t 10 mg 3\ 5 $ 34
? 9AI 9LY !Hn$
O D : IM ; 25 mg 3\ 4 ;9.
!

" #/7$
- IM, SC : G9X?#'>!L&'L >

- IV push : !L&'L >(#IE
Sterile water for Injection,
NSS, D5W, dextrose-saline
combination LY $I$'EX >
$#'E 5 ml :8#!)#9)#$10 mg/
ml
D5W :8#G(#AI 9!)#9)#$
0.1 t 1 mg/ ml ($=E91 mg/
ml)
- IM : :$m4:;#X'$bX ?(
:8#}4(E X'$ :8#E "%J
30 - 90 $ 34
- SC : :$m4:;#X'$bX ?(
:8#}4(E X'$ :8#E "%J
30 - 90 $ 34
- IV Infusion : K(E !L&'
L >E :8# 94AI 9!)M9)#$ 1
mg/ ml :$bN#:8<X:8#'? !MI
15 t 35 mg/ hr :$!(M!9&_':8#
loading dose 0.5 t 1 mg/
kg ? 9(#IE 0.3 mg/ kg/ hr
- IV push : :8#'EX >;# ] :;#
!I% 'EX >$#'E 5 $ 34 FJX>
}4(8% E] A@> K(E$Y E GH
!L&'L >F%D}4(A@>%D < 10
mg/ ml
- 8# 9b"9E }4( Pethidine J Barbiturate !f D!)# $G9XG(#

LD3Y :8#!=( ??D'$
- AI:8#E :$)mD34_bN#HpIE'ENX:$3X $'$!f&_'%( !=(
Orthostatic hypotension
- !f&_'!Hn$ J!3 ' HI(AI:8#E FXbN#HpIEX'$34_LD
!=_994' HI(9 )~@$ K(E!=_9:8#)$ (?_Y ] X'$F%D:8#:$
DED!I% 34_"9_Y !"9'' L;XIE%(' I=?>I%G(# y# 9
" 9 yAIJA\9' HI(G(#F%#I NHFJJ :8#E ?X'GH
LD)~@$JbN#HpIEF?X%D E
- 3Y :8#H"" ID!Hn$(LD!f=_9 )J'')'>E 34_
G9XyN!H%4_E$FH%>
- :;#:$DEDE I" 9 y3Y :8#!=( ?=(E G(# '
y'$E ' LLD!=_9!=(B E:$ 3 t 4 ;9. 8%>:8#E A@>"\(3# E
F%DLD!=(' "N>"\(B E:$ 8 t 12 ;9.
- E $4@LDG9X:;#:$' HI(;$=(!&@'>!$&_'>L ' L!=( toxic
reaction
overdose : (DJJHD" 3"XI$% > ( 8 E:L
9X $? )E E 8I:L!?#$;# pulmonary edema ' !M>"_$ ;
- !MJE : !MJE :8#f#$F"> 34_'\m8BN9= 15 - 30 C
! : Pain relief, respiratory and mental status,
blood pressure, ?IL 3Y > $)'>%Y G"#:$J > E' L
LY !Hn$?#'>:8#E DJ E
UV:
- IM, SC ; onset 10 - 15 $ 34
peak 1 ;9. DED!I%
2 - 4 ;9.
- IV ; onset 5 $ 34
IM, IV, SC
- USFDA Preg Cat C/ D (prolonged use or high doses at

term)

Pancuronium
Bromide
(Pavulon)
4 mg/ 2 ml

/

/

!

" #/ 7$
- !Hn$ neuromuscular blocker of choice

NSS, D5S, D5W - Direct IV : G9X?#'>!L&'L >
- Direct IV : :8#3\
E!I#$bN#HpIE34_94B ID 3Y > $)'>?J8&'G?
RINGER
- IV Infusion : !L&'L >:$" %D% E34_ 20 - 60 $ 34 ? 9?#'>
JfX'> :;#"Y 8JA% E%# 9!$&@'!f&_' :"X
:;#G(#
- IV Infusion : ? 9
endotracheal tube 8&':$ bX ?( :;#"Y 8J
?'J"$'>)'>bN#HpIE
:"X!A&_'>;XIE8 E:L:$ ICU G9X943=D>J
HI(8&'">JD>J
)$ (E 34_:;#:$bN#HpIEF?X%D E)~@$J$@Y 8$
< 1
:
- Test dose : 0.02 mg/ kg !f&_'I( ?'J"$'>
)$ (E !=_9?#$ : 0.03 mg/ kg/ dose :8#@Y G(#3\
5 t 10 $ 34 ? 9?#'>
maintenance : 0.03 t 0.09 mg/ kg/ dose
3\ 30 $ 34 t 4 ;9. ? 9?#'>

J= 1
:
0.06 t 0.1 mg/ kg 8&':8# 0.05 mg/ kg 8%>L
:8# succinyl choline !f&_' :"X endotracheal
tube )$ (E ?X'GH:8# IV bolus 0.01 mg/ kg
$ $ 60t 100 $ 34 8%>L :8#E K("F
F%D8%>L $@$:8# 0.01 mg/ kg 3\ 25 t 60$ 34
- :$ ICU : 0.05 - 0.1 mg/ kg IV bolus
? 9(#IE 0.8 - 1.7 g/ kg/ min 8$~_>A@> 8&':8#
0.1 t 0.2 mg/ kg 3\ 1 t 3 ;9.
E: '\m8BN9= 2 - 8 oC E 34_!8%&'AI3=@> 8%>L

!H(8%'( 2 - 3 ;9.
- 8%>L !L&'L >F%#IA>?I 48 ;9.
7$ :
- :;#!}f DbN#!;4_EI; <!3X $@$
- :8#E )$ ("N>LD!f=_9AI 9y4_F%DAI 9\$F>:$ !=(
tachycardia
- E ' L94"XI$HD'J)'> benzyl alcohol :8#DI>:$
bN#HpIE34_Ff#
- 8# 9b"9I9J diazepam
! : 3Y > $)'>DJJ neuromuscular,
"<< m;4f, electrolyte, Heart rate, BP, Ventilation
status, Cardiac status
overdose : 8E\(8 E:L ( 8 E:L DJJ8I:L
%#9!8%I
- USFDA Preg Cat C

Pralidoxime
Chioride
(2 - PAM)
1g
Ranitidine
(Xanidine,
Ranidine)
50 mg/ 2 ml

/

/

!

" #/7$
- Antidote, Anticholinesterase
- :;#J Organophosphorus poisoning IV ;
IM, SC ;

: 20 t 50 mg/ kg/ dose :8#:$ 1 t 2 ;9.
8%>L $@$:8#3\ 8 t 12 ;9. y# 94 sign )'>
cholinergic !=()~@$
: 1 t 2 g :8#@Y :$ 1 ;9. 8%>L $@$:8#
3\ 8 t 12 ;9. y# 94 sign )'> cholinergic
!=()~@$
- Acetylcholinesterase inhibitor toxicity
: Adult : IV ; 1 t 2 mg ? 9(#IE 250 mg 3\ 5
$ 34L$?'J"$'>
- Histamine H2 Antagonist
- Duodenal, gastric ulcer, GERD

1
16 : IV ; 2 t 4 mg/ kg/
day FJX>:8#3\ 6 t 8 ;9. K(E)$ (E "N>"\(G9X
!=$ 150 mg/ day\
: IV continuous infusion for Zollinger t
Ellison : 1 mg/ kg/ hr ; I()$ ( gastric acid
output 34_ 4 ;9. y# > 10 mEq :8#!f=_9)$ (E
'4 0.5 mg/ kg/ hr K(E)$ (E "N>"\(G9X!=$ 2.5
mg/ kg/ hr
IM, IV intermittent bolus/ infusion
: 50 mg :8#3\ 6 t 8 ;9.
IM , Direct IV, Intermittent IV, Continuous IV
NSS
- Direct IV : 1 g %D% E
:$
SWFI 20 ml 8&' G9X?#'>
!L&'L >:$bN#HpIE34_94B ID
pulmonary edema
- IV Infusion : !L&'L >b>
E 1 t 2 g :$ NSS 'EX
>$#'E 100 ml
- Direct IV : 1 g :8#$ $IX 5 $ 34

- IV Infusion : 1 dose :8#$ $IX 15
t 30 $ 34 G9XAI:8#!MIIX 200 mg/
min
- Direct IV :;#!}f Dm4bN#HpIE94 pulmonary edema 8&'

Infusion G9XG(#!9&_'!?4E9F%#IAI:;#3$34
- AI:;#B E:$ 24 ;9. 8%>L bN#HpIE=$E " f=
! : HR, RR, BP, continuous EKG
- :8#!MI] LD3Y :8#!=(laryngospasm, mucle rigidity
8&' tachycardia
NSS, D5W,
D10W
- IM : G9X?#'>!L&'L >
- Direct IV : !L&'L >J
" %D% E34_:;#G(# 20 ml
- Intermittent IV infusion
: 50 mg :$" %D% E34_
:;#G(#G9X$#'EIX 100 ml
- Continuous IV infusion
: :$" %D% E34_:;#G(#'EX
>$#'E 250 ml (AI 9!)#
9)#$G9X!=$ 2.5 mg/ ml)
- Direct IV : :8#$ $IX 5 $ 34

- Intermittent IV infusion : AI:8#E
$ $IX 20 $ 34
- Continuous IV infusion : AI:8#E
6.25 mg/ hr :$!I% 24 ;9.
- USFDA Preg Cat C

- 8%>!L&'L >F%#IA>?I 48 ;9. 34_'\m8BN9=8#'>
- AI!MJ:8#f#$F">
- :8#'EX >I(!MI' L3Y :8#!=( bradycardia F%D
tachycardia G(#
! : renal function impairement, hepatic
function impairment
- USFDA Preg Cat B

Streptomycin
1 g powder

/

/

- Antituberculosis,aminoglycoside

: TB :
- Daily therapy : 20 t 40 mg/ kg/ day FJX>:8#
3\ 6 t 12 ;9. K(E)$ ("N>"\(G9X!=$ 1 g
- Directly observed therapy (DOT) : 25 t 30
mg/ kg "H( 8C%D 2 A@> K(E)$ ("N>"\(G9X
!=$ 1.5 g/ dose
- DOT : 3 A@>/ "H( 8C, )$ (E 25 t 30 mg/
kg K(E)$ ("N>"\(G9X!=$ 1 g
: TB :
- Daily therapy : 15 mg/ kg/ day K(E)$ (
"N>"\(G9X!=$ 1 g
- Directly observed therapy (DOT) : 25 t 30
mg/ kg "H( 8C%D 2 A@> K(E)$ ("N>"\(G9X
!=$ 1.5 g/ dose
- DOT : 3 A@>/ "H( 8C, )$ (E 25 t 30 mg/
kg K(E)$ ("N>"\(G9X!=$ 1 g
- Enterococcal endocarditis : 1 g :8#3\ 12
;9. $ $ 2 "H( 8C, : 500 mg :8#3\ 12 ;9.
$ $ 4 "H( 8C K(E:8#XI9J penicillin
YC : 10 mg/ kg/ day K(E)$ ("N>"\(G9X
!=$ 750 mg
NSS,D5W
IM
!
- IM : 1 g :$$@Y %_$,
NSS 3.5 - 4.5 ml

- IM : }4(!)# %# 9!$&@'9()$ (:8<X
" #/7$
- 8%>%D% EF%#IAI:;#B E:$ 48 ;9. 34_'\m8BN9=8#'>F%D
14 I$!9&_'!MJ:$?N#!EM$
! : hearing (audiogram), BUN, Cr
- USFDA Preg Cat D

7.5 % Sodium
bicarbonate
(0.9 mEq/ ml)
and 44.6 mEq/
50 ml
Sulperazone
(Cefoperazone
0.5 g +
Sulbactam 0.5
g)

/

/

!

" #/7$
- !Hn$ alkalinizing agent B ID

metabolic acidosis, hyperkalemia
- Cardiac arrest
Infants and children: IV ; 0.5 t 1.0
mEq/ kg/ dose
: IV ; initial 1 mEq/ kg/ dose,
maintenance 0.5 mEq/ kg/ dose
- Metabolic acidosis
Infants and children : HCO3- (mEq)
= 0.3 x weight (kg) x base deficit
(mEq/L) 8&' HCO3- (mEq) = 0.5 x
weght (kg) x [24-serum HCO3(mEq/L)]
: HCO3- (mEq) = 0.2 x weight
(kg) x base deficit (mEq/L) 8&'
HCO3- (mEq) = 0.5 x weight (kg) x
[24-serum HCO3- (mEq/L)]
Direct IV, IV infusion
- )$ ( :8#E 2 - 4 g/ day
3\ 12 ;9.
D5S, D5S/2,
D5W, D10W
- Direct IV :$bN#:8<XF%D!(MG9X
LY !Hn$?#'>!L&'L > LD:;#:$AI 9!)#9)#$ 1
mEq/ ml :$ neonate 8&'!(M' E\$#'E
IX 2 H| LD:;#:$AI 9!)#9)#$ 0.5 mEq/
ml 8&'!L&'L >" %D% E(#IE sterile
water :$'? "XI$ 1:1
- Direct IV : AI:8#E 'EX >;# ]

:$m4 cardiac arrest ' LLD
:8#E 'EX >!MIF%DAI?=(? 9
!=(' )# >!A4E>L
:8#E 'EX >!MIK(E:;#E )$ ( 1
mEq/ kg :8#:$!I% 9 IX 1 t
3 $ 34
- 8%>L !L&'L >F%#IA>?I 24 ;9.

- :8#'EX >I(!MI (10 ml/ $ 34) ' L3Y :8#
hypernatremia, CSF pressure %(%> F%D' L!=(
intracranial hemorrhage
7$ : :$ :8#E @Y AI:8#E :$)$ ($#'E]!f&_'
8%4!%4_E> !=(B ID overdose F%D metabolic alkalosis
:8#E )$ (9 !=$GHL3Y :8#!=(B ID hypokalemia F%D
' L3Y :8#bN#HpIE!=(B ID8I:L!?#$b=(L>8ID
- AIDI> _I)'>E ''$'!"#$!%&'(
! : ?=(? 9B ID) ("9(\%)'> electrolyte
K(E!}f D hypokalemia F%D hypocalcemia ?=(? 9 pH,
ABG F%DD(J sodium bicarbonate 3Y > $)'>G?
K(E!}f D :;#:$DEDE I
- Continuous infusion !L&'L >:$ NSS,

D5NSS K(E94AI 9!)#9)#$"N>"\(!3X J
0.5 mEq/ ml :$ neonate 8&'!(M' E\
$#'EIX 2 H| :;#:$AI 9!)#9)#$ 4.2 %
8&'!L&'L >" %D% E 7.5 % sodium
bicarbonate (#IE D5W :$'? "XI$ 1:1
K(EAI 9!)#9)#$"N>"\(!3X J 0.5 mEq/
ml
D5W, NSS,
D5S/4, D5S
- Continuous infusion :
'? !MI)'> :8#E !3X J 2
t 5 mEq/ kg :$!I% 9 IX 4
t 8 ;9. G9XAI:8#9 IX 50
mEq/hour :8#:$!(MAI94
'? !MI)'> :8#E %(%> K(E
'? !MI"N>"\()'> :8#E
!3X J 1 mEq/ kg/ hr
- IM : 1 vial :$$@Y %_$ 1.5 - 2 ml

- Direct IV : 3 $ 34
- Direct IV : 1 vial :$$@Y %_$ 3 t 3.5 ml - Infusion : 15 - 60 $ 34
- Infusion: :$" %D% E34_:;#G(#'EX >$#'E
10 ml
- USFDA Preg Cat C

- 8%>%D% EF%D!L&'L >F%#IA>?I 24 ;9. 34_'\m8BN9=8#'>
F%D?N#!EM$
- USFDA Preg Cat B

/

/

!

" #/7$
Streptokinas
(Streptase ) 1.5 mu
- Thrombolytic agent :;#:$B ID

severe deep vein thrombosis,
pulmonary emboli, myocardial
infarction F%DB ID34_94 '\(?$)'>
%=_9!%&'(
- Acute MI : IV 1.5 mU $ $ 60 $ 34
- Acute pulmonary embolism : IV 3
mU $ $ 24 ;9.
D5W, NSS
- %D% EE (#IE NSS H=9 ? 5 ml

K(E!?=9'EX >;# ] J=!Im)# >)I(
F%#I89\$F%D!'4E>)I('EX >;# ]
G9XAI!)EX )I( L $@$!L&'L >
?X'(#IE NSS/ D5W :8#G(#H=9 ?
3@>89(!Hn$ 45 ml F?X' LLD
!L&'L >9 IX $4@ K(E:;#
" %D% EH=9 ? 45 ml !L&'L >
:$H=9 ?"N>"\( 500 ml
AI 9!)#9)#$"N>"\(A&'
1.5 mu/ 50 ml
- IV Infusion pump !L&'L >E (#IE
" %D% E D5W, NSS, Ringer's
Lactate
- continuous IV Infusion "Y 8J Pulmonary

embolism, deep vein thrombosis, arterial
embolism 8&' thrombosis 94(>$4@ :
- loading dose :$ pulmonary embolism,
deep vein thrombosis, arterial embolism
8&' thrombosis :8#E 34_!L&'L >F%#IbX $3 >
peripheral IV line K(E:;# infusion pump K(E
:8# 250,000 IU :$!I% 9 IX 30 $ 34
- maintenance dose :8#bX $ infusion pump
:$'? !MI 100,000 IU/ hr "Y 8J
pulmonary embolism LD:8# continuous IV
Infusion !Hn$!I% 24 ;9. "Y 8J arterial
embolism 8&' thrombosis LD:8# continuous
IV Infusion !Hn$!I% 24 t 72 ;9. "Y 8J
deep vein thrombosis LD:8#!Hn$!I% 72 ;9.
-"Y 8J coronary artery thrombi :8#E 34_!L&'
L >F%#IbX $3 > peripheral IV line K(E:;#
infusion pump K(E:8#'? !MI!Hn$ 1.5 mU
?X';9. !Hn$!I% 1 ;9. G9XLY !Hn$?#'>:8#
maintenance dose
- 8%>%D% EF%#IA>?I 24 ;9. :$?N#!EM$ F%D 8 ;9.

34_'\m8BN9=G9X!=$ 25 OC Hl'>$F">
- !9&_'!=_9?#$ ' L!=(AI 9($K%8=??_Y 8I
:L!?#$!MI8&';# b=(H?= L$' Ly~>;M'AG(# (>$@$L~>
AI8E(E 'EX >;# ] !9&_'!=_9?#$ F%D
" 9 y :8#E %\X9A'C?=KA"!?''E(C!f&_'
Hl'>$G(# !;X$ :8#E Methylprednisolone Inj 100 200 mg X'$!=_9:8#E Streptokinase 10 $ 34
- F9#LDG9XF$D$Y :8#:;# heparin :$D8IX >:8#E
streptokinase F?X' L:;#8%>L $@$G(#!f&_'%('?
!"4_E>?X' %J!Hn$@Y )'> thrombosis F%D
pulmonary emboli K(E:8# heparin 8%>L 8E\(:8#
E streptokinase GHF%#IHD9 m 3-4 ;9. 8&'
!9&_'?ILAX PTT G(#$#'EIX 100 I=$ 34
overdose : !%&'(Y !( G8% !%&'(''? 9G$ L@Y
!%&'(
! : BP, PT, PTT, fibrinogen level
- 3Y Skin test 100 u (15 t 20 min) X'$}4(
-% ! IM
- USFDA Preg Cat C

Succinycholine
(Suxamethonium
chioride)
50 mg/ ml, 10 ml

/

/

- :;#"Y 8JA% E%# 9!$&@'!f&_' :"X
NSS, D5W, D5S
endotracheal tube 8&':$ bX ?(
- IM : 2.5 - 4 mg/ kg )$ (E I9G9X!=$
150 mg AI}4(:$%# 9!$&@' deltoid F%D}4(
:8#%~

: IV ; !=_9?#$ 1-2 mg/ kg ? 9(#IE
0.3 t 0.6 mg/ kg 3\ 5-10 $ 34 ? 9?#'>
!$&_'>L E 94AI 9!"4_E>3Y :8#!=( malignant
hyperthermia L~>G9XF$D$Y :8#:;#E FJJ
continuous infusion :$!(M
: IV ; 1 t 1.5 mg/ kg ? 9(#IE 0.04 0.07 mg/ kg 3\ 5-10 $ 34 K(E)$ (E I9
G9X!=$ 150 mg
Continuous infusion ; 10 - 100 g/ kg/ min
8&'
0.5 - 10 mg/ min
Direct IV, IV Infusion, IM
!

- Direct IV : G9X?#'>!L&'L >
- Direct IV : :8#:$!I% 10 t 30 I=$ 34
- IV Infusion : !L&'L >:8#94AI 9 bX $3 >" E:8#" $@Y
!)#9)#$ 0.1 - 0.2 %
- Continuous IV Infusion : :;#AI 9!)#9)#$
- IM : }4(:8#%~
1 t 2 mg/ ml :8#E bX $3 >" E:8#" $@Y
K(E!=_9:8#E :$'? !MI 2.5 mg/ min
8%>L $@$HJ)$ (!Hn$ 0.5 t 1.0 mg/
min )~@$J ?'J"$'>)'>bN#HpIE G9XAI
!=$ 10 mg/ min
* G9XF$D$Y :8#E FJJ intermittent IV
Infusion !$&_'>L :8#E !Hn$DEDLD3Y
:8#!=( tachyphylaxis F%D prolonged
apnea
- G9X!)# $J Calcium carbonate,
Pentobarbital F%D Thiopental
" #/ 7$
- 8%>!L&'L >F%#IA>?I34_'\m8BN9=8#'> 24 ;9.
- 8 :;#" %D% EG9X89(:8#3=@>" %D% E$@$
7$ :
- B ID34_!Hn$" !8?\3Y :8#!=( prolonged
neuromuscular blocked G(#FX electrolyte
imbalance (hypokalemia, hypoclcemia,
hypermagnesemia, hypernatremia), Hypothermia,
KA)'>bN#HpIE!;X$ myasthenia gravis, polymyositis
8&' :;#E 34_94 drug interaction G(#FX Inhaled
anesthetics, calcium channel blockers,
antiarrythmics, aminoglycosides, vancomycin,
clindamycin, tetracycline, cyclosporin
- :8# atropine X'$:8#E LD;XIE%( !=(
bradycardia
- :8#E %\X9 nondepolarizing neuromuscular
blocking agents (pancuronium, vecuronium,
atracurium) X'$:8#E 3 - 5 $ 34 LD;XIEHl'>$HD
%( !=(' (>?X'GH$4@G(# : fasciculations,
myalgia, myoglobinuria, increased intragastric
pressure, increased intracranial pressure
! : blood pressure, heart rate, '\m8BN9=
F%D ?=(? 9D(J)'> muscle relaxation
overdose : respiratory paralysis, cardiac arrest
E : 2 t 8 C y# 'ENX:$NHFJJb>F8#>G9X
LY !Hn$?#'>F;X!EM$
- USFDA Preg Cat C

Thiopental
sodium
1 g powder

/

/

!

- :;#E :8# Test dose X'$K(E :;#

25 t 75 mg (1 t 3 ml )'>" %D% E!)#9)#$
2.5 %) !f&_'?IL"'JAI 93$?X'E F%D
Ff#E K(E">!?:$!I% 60 I=$ 34
- ;$Y "%J :
Infant : 5 t8 mg/ kg

1 12 : 5 t 6 mg/ kg
: 3 t 5 mg/ kg
- "B ID "%J :

: 1 mg/ kg ? 9AI 9LY !Hn$
: 25 - 100 mg ? 9LY !Hn$
- ' ; :

: 2 t 3 mg/ kg/ dose
: 75 t 250 mg/ dose @Y G(#? 9
LY !Hn$
0.45 % NaCI,
NSS, D5W
- Direct IV : :;#)$ (E 500 mg

9 %D% E(#IE sterile water,
D5W 8&' NSS LY $I$'EX >$#'E
20 ml LDG(#AI 9!)#9)#$ 2.5 %
y# :8#:$AI 9!)#9)#$"N>LY 3Y :8#
!=( hemolysis
- Intermittent IV Infusion : :;#:$
AI 9!)#9)#$ 2 t 5 % :$ D5W,
NSS K(EH?=:;#AI 9!)#9)#$ 2
8&' 2.5 %
- Continuous IV Infusion : :;#b>
E 34_%D% EF%#I)$ ( 200 t 400
mg 9 !L&'L >(#IE NSS 8&'
D5W LY $I$ 100 ml LDG(#AI 9
!)#9)#$ 0.2 t 0.4 % G9XAI:;#
sterile water !Hn$?I!L&'L >
!$&_'>L LD3Y :8#!=( hemolysis
- direct IV :;#AI 9!)#9)#$

2.5 % K(E:8#)$ (E 25 mg
:$!I% 9 IX 1 $ 34 K(EHJ
)$ (E ? 9b%34_?#'>
:8#E 'EX >I(!MILD3Y :8#!=(
' overdose ~_>LD94 (
DJJ8 E:L'EX >\$F> AI 9
($K%8=??_Y %( cardiac output
:8#E FJJ direct IV LD:8#E
bX $3 >" E:8#" $@Y
- Intermittent IV Infusion :;#
AI 9!)#9)#$ 2.5 % :8#E :$
!I% 9 IX 10 t 60 $ 34 K(E
AI 9!)#9)#$"N>"\(!3X J 50
mg/ min
- Continuous IV Infusion :;#
" %D% E34_94AI 9!)#9)#$ 0.2 t
0.4 % K(Ey# :8#:$AI 9!)#9)#$
0.2 % :8#:$'? !MIG9X!=$ 50
ml/ min
" #/ 7$
- b>E 34_%D% EF%#ILD94AI 9A>?I 3 I$ 34_'\m8BN9=8#'>F%D
7 I$ :$?N#!EM$
- !$&_'>L E G9X94 preservative 8%>L 34_!L&'L >F%#IAI:;#
B E:$ 24 ;9.
7$ :
- :8# prolong continuous infusion ' L3Y :8#!=(
respiratory F%D circulatory depression
- bN#HpIE34_94B ID3$?X'E barbiturates 8&' alcohol ' L
LY !Hn$?#'>:8#E :$)$ ("N>)~@$
- 8%4!%4_E> :8#E FJJ subcutaneous F%D intra-arterial
!$&_'>L E ' L3Y :8#!=(!$&@'!E&_'? EF%D8%\(%'
! : ?=(? 9I( vital sign 3\ 3 - 5 $ 34
E$A : '\m8BN9= 15 t 30 C
- USFDA Preg Cat C

/

/

Terbutaline
(Bricanyl)
0.5 mg/ ml
- Bronchodilator, Tocolytic agent

- Bronchostriction

< 12 : SC ; 0.005 t 0.01
mg/ kg/ dose :8#3\ 15 t 20 $ 34 :8#
3 dose )$ ("N>"\(G9X!=$ 0.3 mg/ kg

> 12 : SC ;
0.25 mg/ kg/ dose y# LY !Hn$' L:8#
@Y '4A@>B E:$ 15 t 30 $ 34 )$ (
"N>"\(G9X!=$ 0.5 mg/ kg
- Premature labor
: IV ; 2.5 t 10 g/ min !f=_9)~@$
G(#3\ 10 t 20 $ 34 )$ ("N>"\(G9X!=$
17.5 t 30 g/ min
SC, IV Infusion
- :;#:$ Hemophillia Patient :$D8IX >
D8IX > y'$$!f&_'%( F%DHl'>$
!%&'(''

: IV ; 10 mg/ kg :8#
3$34X'$bX ?( 8%>L $@$:8# 25 mg/
kg/ dose K(E JHD3 $I$%D 3 t
4 A@>
D5W, NSS
- Infusion : E 5 mg %D% E:$

D5W :8#G(#AI 9!)#9)#$ 5 g/ ml
- IV Infusion : :8#$ $'EX >$#'E 12 ;9.
- 8%>L !L&'L >F%#IA>?I 48 ;9.

- $=E9:;# D5W LD:;# NSS !9&_'bN#HpIE94)#'8# 9:;#
Dextrose !3X $@$
! : lung sound, pulse, BP, wheezing
after admin call physician
- USFDA Preg Cat B
NSS, D5W,
D10W,
RINGER
IV : !L&'L >'EX >$#'E 50 ml :$

" %D% E34_:;#G(#
- G9X!=$ 1 ml/ $ 34 :8#'EX >I(!MI' L

3Y :8#!=( hypotension
- :8#3 > IM D9(DI> !=( tissues or

nerves damage AI8%4!%4_E> }4(:$34_!(=9
Tranexamic acid
250 mg/ 5 ml (5%)
Intermittent IV, IM
!

" #/7$
- USFDA Preg Cat B

Trastuzumab
(Herceptin) 440 mg
+ SWFI + diluent
benzyl alcohol

/

/
- Antineoplastic agent
- Initial loading dose : 4 mg/ kg
- IV Maintenance dose : 2 mg/ kg

SWFI
!
- b"9!L&'L >J SWFI
20 ml 8# 9!)EX LDG(#
" %D% E = 21mg/ ml

- IV Infusion loading dose :8#$ $ 90 $ 34
- Maintenance dose :8#$ $ 30 $ 34 y# 3$
G(#
IV, IV Infusion
Vancomycin
(Vancocin inj)
500 mg
NSS,D5W,D - Intermittent IV : %D% E

- Antibiotic, Miscellaneous
10W, D5S, 500 mg :$ D5W 8&' NSS
- )$ ( :;#3_IGH :
Sodium
Infants >1 month and Children: IV ;
10 ml F%#IL~>HJH=9 ?(#IE
Bicarbonate NSS 8&' D5W :8#AJ
10 t 15 mg/ kg 3\ 6 ;9.
3.75 %
Adult : IV : 2 t 3 g/ day (20 t 45 mg/
100 - 200 ml
kg/ day) FJX>:8#3\ 6 t 12 ;9.)$ (
- IV Infusion : 1 - 2 g :$
"N>"\(G9X!=$ 3 g/ day
" %D% E34_:;#G(# drip 24 ;9
Intermittent IV, IV Infusion
- IV Infusion : 24 ;9. (daily dose)

- Intermittent IV : 'EX >$#'E 60 $ 34 AI 9
!)#9)#$"\(3# EG9X!=$ 5 mg/ ml
" #/7$
- X'$b"9!MJE :$?N#!EM$ 2 - 8 C 8&' 38 t 48 F
8%>b"9J SWFI F%#I!MJG(# 28 I$:$?N#!EM$
- 8# 9b"9I9J D5W F?X dilute (#IE NSS
'ENXG(# 24 ;9. 34_'\m8BN9=8#'> F?XAI!MJ:$?N#!EM$
'\m8BN9= 2 - 8 C
- monitor : cadiac dysfunction and vital sign
- USFDA Preg Cat B
Vancomycin
(Vancocin inj)
500 mg

/

/

!

" #/7$
Vecuronium
Bromide
(Vecuron, Norcuron)
4 mg/ml
- Neuromuscular-Blocking Agents,
D5W,NSS,
D5S,
RINGER
- Direct IV : %D% EE 10 mg :$
$@Y %_$ 10 ml
- IV Infusion : %D% EE 10 t 20
mg :$" %D% E34_:;#G(#'EX >$#'E
100 ml
- Direct IV : - 1 $ 34
- IV Infusion : '? !MI)'> :8#E 0.8 t
- 8%>!L&'L >F%#IA>?I 1 I$K(E!MJGI#:$?N#!EM$

- !L&'L >:$ bacteriostatic water for injection A>
?I 5 I$
"Y 8JA% E%# 9!$&@'!f&_' :"X

endotracheal tube 8&':$ bX ?(
:;#"Y 8J :"X!A&_'>;XIE8 E:L
: !=_9?#$:8#E :$)$ ( 0.08 t
0.1 mg/ kg )$ (E ?X'GH:8# 0.01 t
0.015 mg/ kg K(E:8#8%>L )$ (E
!=_9?#$ 20 t 40 $ 34 ?X'L $@$:8#3\
12 t 15 $ 34? 9AI 9LY !Hn$8&':8#
FJJ continuous infusion !=_9:$)$ (
1 g/ kg/ min (0.001 mg/ kg/ min)

: 0.5 t 1 mg/ kg/ hour !(M' E\
10 t 17 H| )$ (E !89&'$)'>bN#:8<X
!(M' E\$#'EIX 10 H| ' L?#'>:;#
)$ (E !=_9?#$"N>IX
Direct IV ,IV Infusion
1.2 g/ kg/ min
- USFDA Preg Cat C

Verapamil
(Isoptin)
5 mg/ 2 ml

/

/

- Antiarrhythmic Drugs
- Supraventricular Tachyarrhythmia
!(M' E\ < 1 H| : IV ; 0.1 t 0.2 mg/ kg
:8#@Y 3\ 30 $ 34
!(M' E\ 1 t 15 H| : IV ; 0.1 t 0.3 mg/
kg )$ ("N>"\(G9X!=$ 5 mg/ dose :8#
@Y G(#'4A@>8%>L A@>F 15 $ 34
K(E)$ ("N>"\(G9X!=$ 10 mg/ dose
bN#:8<X : IV ; 2.5 t 5 mg :8#@Y G(#'4
A@>8%>L A@>F 15 t 30 $ 34 :$
)$ ( 5 t 10 mg K(E)$ (E I9
"N>"\(G9X!=$ 20 mg
D5W, NSS,
RINGER
Direct IV,IV Infusion
!
- IV : G9X?#'>!L&'L >K(E:8##
3 > Y - site 8&' 3 - way
- Infusion : !L&'L >:8##G(#
1 mg/ml

- Direct IV : 2 3 $ 34
- Infusion : 5 - 10 mg/ ;9
" #/7$
- G9XAI!MJ" %D% E34_!8%&':; #F%D'EX :;#y#
" %D% E94"4 8&'94?D'$8# 9:;#XI9J sodium
bicarbonate solution in saline 3 > IV line DI>
!=( hypotension, dizziness ,flushing
- !MJ GI#34_'\m8BN9=8#'> 8# 9F;XF)M>
- USFDA Preg Cat C

" ("7)
Ampicillin + sulbactam (Unasyn)
!(Reconstitution)"!@"
IV bolus
/7!!
7!7 $$ !
SWFI, NSS, 5DW, 5DN/2,
Lactated Ringer (1.5 g : 3.2 ml )
Amoxycillin + clavulanic (Augmentin,

Cavumox)
SWFI (1.2 g : 20 ml)

- IV ;# ] !(=$E 3 - 4 $ 34
:;#B E:$ 20 $ 348%>b"9
Aztreonam (Azactam)
NSS, SWFI (1 g : 6 - 10 ml)
48 ;9. 34_ 15 - 30 C
7 I$ 34_ 2 - 8 C
Cefamandole (Mandol)
SWFI, 5DW, NSS (1g : 10 ml)
Cefoperazone (Cefobid)
5DW, 10DW, 5DS, NSS, SWFI,

Normosol R , Normosol M and
5%dextrose inj., 5 % dextrose and
0.2% NSS inj (1 g : 2.8-5.0 ml)
24 ;9. 34_ 25 C
96 ;9. 34_ 5 C
24 ;9. 34_ 15-25 C
5 I$ 34_ 2-8 C
!}f D34_AI 9!)#9)#$34_Y 8$(
_"_ (Dilution of IV fluids) @"

IV Infusion
/7!!
7!7 $$ !
SWFI, NSS, 5DW, 5DN/2,
- SWFI, NSS: 8 ;9. 34_ 25 C F%D
Lactated Ringer
48 - 72 ;9.34_ 4 C
- 5DW: 2-4 ;9.34_ 25 C F%D 4 ;9.34_ 4 C
- 5DN/2: 4 ;9.34_ 25 C F%D 4 ;9.34_ 4 C
- LR: 8 ;9.34_ 25 C F%D 24 ;9.34_ 4 C
NSS, Sodium lactate 1/6M, Ringer's soln.,
- SWFI, NSS, Sodium lactate 1/6M :
Lactated Ringer , KCl or
4 ;9.34_ 25 C
NaCL infusion (1.2 g : 100 ml)
- SWFI, NSS : 8 ;9.34_ 5 C
- m4 IV drip : E 1.2 g %D% E:$ water 8&' - Ringer's soln , LR, KCl or NaCL :
NSS 100 ml drip 30 - 40 $ 34
3 ;9. 34_ 25 C
SWFI, NSS, Ringer's inj, Lactated Ringer's inj, 48 ;9.34_ 15 - 30 C
5DW, 10DW, 5DS, 5D/N/2, 5D/N/4,
7 I$.34_ 2 - 8 C
Sod.lactate(M/6) !Hn$?#$ (1 g : 50 ml 'EX >$#'E) $@Y E 34_ Conc. > 2% w/v :8#:;#3$34
AI 9!)#9)#$"\(3# EG9X!=$ 2 % w/v
8%>b"9 E!I#$:$ WFI, NSS y# !MJ
'\m8BN9= ?#'>:;#B E:$ 48 ;9. 8&'
y# !MJ:$?N#!EM$ ?#'>:;#B E:$ 7 I$
NSS, 5DW, 10DW, 5DS, 5DN/2, 5DN/4,
sod.lactate inj (M/6)
5DW, 10DW, 5DS, NSS, Normosol R,
24 ;9. 34_ 15-25 C
Normosol M and 5%dextrose inj, 5%dextrose 5 I$ 34_ 2-8 C
and 0.2% NSS inj, LR, 5%dextrose and
!}f D34_AI 9!)#9)#$34_Y 8$( (N E%D!'4E(
lactated ringer's inj
!'" Y JE
Cefoperazone + sulbactam
(Sulperazon)
IV bolus
/7!!
7!7 $$ !
5DW, 10DW, 5DS, NSS, WFI
- 24 ;9. 34_ 15 - 25 C F%D
1 g/ 2.8 8&' 5 ml
5 I$ 34_ 2-8 C
!}f D34_AI 9!)#9)#$34_Y 8$(
SWFI ( 1 g : 4 ml)
- 24 ;9. 34_'\m8BN9=8#'>
* "'Jy 9L J=3
Cefotiam (Ceradolan)
SWFI, NSS, 5DW (1 g : 5 -20mL)
Cefpirome (Cefrom)
SWFI (1 g : 10 ml)
Cefuroxime (Zinacef)
SWFI (750 mg : 6 ml)
Fosfomicin
Fusidate sodium (Fucidin)
[$ infuse $8
SWFI, NSS, 5DW (1-2g:20mL)

Buffer solution (500 mg : 10 ml)
" ("7)
Cefoperazone (Medocef)
Gatifloxacin (Tequin)

IV Infusion
/7!!
7!7 $$ !
5DW, 10DW, 5DS, NSS , WFI
- 24 ;9. 34_ 15-25 C
F%D 5 I$ 34_ 2-8 C
!}f D34_AI 9!)#9)#$34_Y 8$(
5DW, NSS, SWFI, 5DS,5DN/4
(1 g : 20 ml)
IV push:8%> reconstituted }4('EX >$#'E
3$ 34
IV drip: %D% E?X'$@Y E !(4EI$ L$G(# 20 ml
drip 15 - 60 $ 34
:;#B E:$ 8 ;9. G9XDJ\'\m8BN9=
Glucose solution, electrolyte solution or amino
acid prep
6 ;9. 34_ <25 CF%D 24 ;9. 34_ 2-8 SWFI, NSS, Ringer's soln, 5DW, 10DW, 6DS 6 ;9.34_ <25 C F%D 24 ;9. 34_ 2-8 C
C
(1 g :100 ml)
- 5 ;9.34_ < 25 C
SWFI. (1.5 g : 50 ml) NSS, 5DW, 0.18%NSS + - 24 ;9. 34_ < 25 C F%D 72 ;9. :$?N#!EM$
F%D 48 ;9. :$?N#!EM$
4% dextrose inj.,
24 ;9. 34_'\m8BN9=8#'>
y# !L&'L >IX $4@ (1.5g/ 50ml) LD'ENX Sodium lactate inj etc.
G9XG(#DJ\AI 9!)#9)#$
G(# 24 hr 34_ < 25 C F%D

72 hr y# !MJ:$?N#!EM$
7 I$G9XG(#DJ\'\m8BN9=
NSS, 5DW (1-2 g: 100 - 500 ml )
:;#89(B E:$ 24 ;9.
NSS, 5DW (500 mg : 250 - 500 ml ) infuse :;#89(B E:$ 24 ;9.
2 ;9.
WFI, NSS, 5DW, Lactated Ringer and 5%
14 I$ :$?N#!EM$ (2 - 8 C) 8&'
Dextrose injection,
34_ 20 - 26 C
5% Sod.Bicarbonate injection

" ("7)
Levofloxacin (Cravit)
Meropenem
Piperazillin
IV bolus
/7!!
7!7 $$ !
AI:;#:8#89(B E:$ 3 ;9.
8%>94 !H(:;#E
SWFI (250 mg : 5 ml)
- 8 ;9. 34_ 15-25 C
F%D 48 ;9.34_ 4 C
SWFI (2 g : 10 ml)

IV Infusion
/7!!
7!7 $$ !
NSS, 5DW, 2.5% Dextrose in Ringer solution AI:;#:8#89(B E:$ 3 ;9. 8%>94 !H(
infuse 60 $ 34
:;#E
NSS, 5DW, 10DW,5DS, 5DN/4, 2.5% or
- NSS: 8 ;9.34_ 15-25 C F%D 48 ;9. 34_ 4
10% mannitol !Hn$?#$ (250 mg -1 g :
C
50-200 ml )
- 5DW, 5DS, 5DN/4, 2.5% or
10% mannitol : 3 ;9.34_ 15-25 C
14 ;9.34_ 4 C
- 10DW: 2 ;9.34_ 15-25 C
F%D 8 ;9.34_ 4 C
IV fluid 34_:;#G(# : 5DW, NSS, 5DS,
!9&_'b"9J cephazolin, flucloxacillin,
Lactated Ringer, etc (2 g : 'EX >$#'E 50 ml) cephamandole, 8&' cefoxitin :$ 5DW,
NSS 8&' Lactated Ringer " 9 y'ENXG(#
24 ;9. 34_'\m8BN9=8#'> 8&' 48 ;9. 34_ 4 C

Injectable Drug Data

Uploaded by

Document Information

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Injectable Drug Data

Uploaded by

Copyright:

Available Formats

Injectable Drugs Data of Banglamung Hospital, Department of Pharmacy, Chonburi

-  !"#$!%&'()'( (sclerosing of

- Antidote E paracetamol 300 mg/ kg

!L&'L >:$" %D% E34_:;#G(#

Injectable Drugs Data of Banglamung Hospital, Department of Pharmacy, Chonburi

Direct IV (G9X$=E9:;#!$&_'>L :8#!MI!=$GH

- Antifungal !=_9?#$ 0.25 mg/ kg F%D

IM, Direct IV, IV Infusion

D5W, D5S/2, NSS, - IM : 250 mg, 1 gm :$$@Y %_$

- USFDA Preg Cat C

- USFDA Preg Cat B

Injectable Drugs Data of Banglamung Hospital, Department of Pharmacy, Chonburi

-  B ID Ventricular fibrillation F%D unstable

- Rapid, Slow, Maintenance :;#

Injectable Drugs Data of Banglamung Hospital, Department of Pharmacy, Chonburi

- USFDA Preg Cat C

Injectable Drugs Data of Banglamung Hospital, Department of Pharmacy, Chonburi

- !Hn$ neuromuscular blocker of choice "Y 8JbN#HpIE NSS, D5W,

- Direct IV ' LG9XLY !Hn$?#'>

- Direct IV :;#!}f D!9&_'

- Initial bolus ' LG9X?#'>!L&'L >

Direct IV, IV Infusion

- USFDA Preg Cat C

Injectable Drugs Data of Banglamung Hospital, Department of Pharmacy, Chonburi

- Central Anticholinergic drug

IM, Direct IV, IV Infusion

D5W, D5S, NSS - IM : %D% EE 250 mg :$$@Y %_$ - Direct IV : 3 t 4

- USFDA Preg Cat C

- USFDA Preg Cat C,D at near term

Injectable Drugs Data of Banglamung Hospital, Department of Pharmacy, Chonburi

Calcium gluconate - Hl'>$F%D B ID hypocalcemia, :;#"Y 8J

!L&'L >(#IE NSS "Y 8J

- G9XAI:8#E FJJ SC F%D IM !$&_'>L LD3Y :8#

Direct IV, IV Infusion

- USFDA Preg Cat C

Injectable Drugs Data of Banglamung Hospital, Department of Pharmacy, Chonburi

NSS, D5W, D10W, - IM : %D% EE 1 g :$$@Y %_$ - Direct IV : 3 - 5 $ 34

- USFDA Preg Cat B

Injectable Drugs Data of Banglamung Hospital, Department of Pharmacy, Chonburi

- Antibiotic (Cephalosporins 3rd generation)

%D% Eb>E 1 g (#IE$@Y %_$

- USFDA Preg Cat B

- USFDA Preg Cat B

Injectable Drugs Data of Banglamung Hospital, Department of Pharmacy, Chonburi

Direct IV, IV Infusion

NSS, D5W, D10W

- Direct IV : 1 g :$$@Y %_$

- USFDA Preg Cat B

Injectable Drugs Data of Banglamung Hospital, Department of Pharmacy, Chonburi

%D% Eb>E 1 g :$" %D% E

IM, Direct IV, IV Infusion

- IM, Direct IV : G9X?#'>!L&'L >

- USFDA Preg Cat D

- USFDA Preg Cat B

Injectable Drugs Data of Banglamung Hospital, Department of Pharmacy, Chonburi

Direct IV, IV Infusion

- Direct IV $Y b>E %D% E(#IE$@Y %_$34_

- Direct IV :8# 6.25 mg

- 8%>L %D% EE F%#IAI:;#3$34 8# 9F;X!EM$!$&_'>L E

Injectable Drugs Data of Banglamung Hospital, Department of Pharmacy, Chonburi

disorders, panic disorders :;#!Hn$E ">J

- IM, Direct IV G9X?#'>!L&'L >

- USFDA Preg Cat D

Injectable Drugs Data of Banglamung Hospital, Department of Pharmacy, Chonburi

- !"#$!%&'()'( (sclerosing of

!L&'L >:$" %D% E34_:;#G(#

Direct IV (G9X$=E9:;#!$&_'>L :8#!MI!=$GH

- Antifungal !=_9?#$ 0.25 mg/ kg F%D

D5W, D5S/2, NSS, - IM : 250 mg, 1 gm :$$@Y %_$

- B ID Ventricular fibrillation F%D unstable

- !Hn$ neuromuscular blocker of choice "Y 8JbN#HpIE NSS, D5W,

D5W, D5S, NSS - IM : %D% EE 250 mg :$$@Y %_$ - Direct IV : 3 t 4

Calcium gluconate - Hl'>$F%D B ID hypocalcemia, :;#"Y 8J

!L&'L >(#IE NSS "Y 8J

- G9XAI:8#E FJJ SC F%D IM !$&_'>L LD3Y :8#

NSS, D5W, D10W, - IM : %D% EE 1 g :$$@Y %_$ - Direct IV : 3 - 5 $ 34

%D% Eb>E 1 g (#IE$@Y %_$

- Direct IV : 1 g :$$@Y %_$

%D% Eb>E 1 g :$" %D% E

- Direct IV $Y b>E %D% E(#IE$@Y %_$34_

- 8%>L %D% EE F%#IAI:;#3$34 8# 9F;X!EM$!$&_'>L E

- Antiarrthymic agent, B ID

D5W, NSS, D10W, - G9X?#'>!L&'L >8&'!L&'L >E

D9(DI> AI%()$ (E !=_9?#$F%D)$ (?X'!$&_'>!9&_'

Direct IV, IM (9HI( G9XAX'E:;#)

Dobutamine Lyophilized powder A@>F:8#b"9

- 8%>%D% EF%#IA>?I 24 ;9. 34_'\m8BN9=8#'>

250 mg !L&'L >:$" %D% E 1000 ml G(#

" %D% E)'> dobutamine ' L!=("4;9fN ~_>LD

Continuous IV Infusion S

- :8# IV Infusion central line 8&' !"#$!%&'((Y :8<X F%D AI

NSS, D5W, D10W, !L&'L >:$" %D% E34_:;#G(#:$

- Colony - Stimulating Factor, anemia

- Hl'>$F%D thromoembolic disorders

- Direct IV : G9X?#'>!L&'L >8&'!L&'

- 8 }4(3 > IV AI}4(;# ] !f&_'Hl'>$ !=( Flushing

- y# :8#:$'? 34_;# !=$GH' L3Y :8#!=(!f#'A%_> DI$

- 8%>b"9!f&_':8# IV Infusion F%#I AI:;#B E:$ 24 ;9.

D5W, D10W, NSS, - b"9E 500 mg J

- General anethetic, :;#;$Y "%J

(E }4( IV " 9 y!L&'L >

- :;# B ID ventricular arrhythmias L

- " %D% E8%>b"9F%#I?#'>:;#:8#89(B E:$ 12 ;9.